<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">NeuroImmune Pharm Ther</journal-id><journal-id journal-id-type="iso-abbrev">NeuroImmune Pharm Ther</journal-id><journal-id journal-id-type="pmc-domain-id">3965</journal-id><journal-id journal-id-type="pmc-domain">degruytersd</journal-id><journal-id journal-id-type="publisher-id">nipt</journal-id><journal-title-group><journal-title>Neuroimmune Pharmacology and Therapeutics</journal-title></journal-title-group><issn pub-type="epub">2750-6665</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>De Gruyter Funded Articles</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10474379</article-id><article-id pub-id-type="pmcid-ver">PMC10474379.1</article-id><article-id pub-id-type="pmcaid">10474379</article-id><article-id pub-id-type="pmcaiid">10474379</article-id><article-id pub-id-type="pmid">38013836</article-id><article-id pub-id-type="doi">10.1515/nipt-2023-0004</article-id><article-id pub-id-type="publisher-id">nipt-2023-0004</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Substances of abuse and their effect on SAR-CoV-2 pathogenesis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Antwi</surname><given-names initials="I">Ivy</given-names></name><xref rid="j_nipt-2023-0004_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Watkins</surname><given-names initials="D">Destiny</given-names></name><xref rid="j_nipt-2023-0004_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pedawi</surname><given-names initials="A">Alahn</given-names></name><xref rid="j_nipt-2023-0004_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ghrayeb</surname><given-names initials="A">Atheel</given-names></name><xref rid="j_nipt-2023-0004_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Van de Vuurst</surname><given-names initials="C">Christine</given-names></name><xref rid="j_nipt-2023-0004_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-3350-8527</contrib-id><name name-style="western"><surname>Cory</surname><given-names initials="TJ">Theodore J.</given-names></name><xref rid="j_nipt-2023-0004_aff_001" ref-type="aff"/><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:tcory1@uthsc.edu">tcory1@uthsc.edu</email></contrib><aff id="j_nipt-2023-0004_aff_001"><institution content-type="dept">Department of Clinical Pharmacy, College of Pharmacy</institution>, <institution content-type="university">University of Tennessee Health Science Center</institution>, <city>Memphis</city>, <state>TN</state>, <country country="US">USA</country></aff></contrib-group><author-notes><corresp id="cor1"><bold>Corresponding author: Theodore J. Cory</bold>, PharmD, PhD, <institution content-type="dept">Department of Clinical Pharmacy</institution>, <institution content-type="university">University of Tennessee Health Science Center College of Pharmacy</institution>, <addr-line>881 Madison Avenue</addr-line>, <city>Memphis</city>, <state>TN</state>, <addr-line>38163</addr-line>, <country country="US">USA</country>, Phone: 901 596 4000, E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:tcory1@uthsc.edu">tcory1@uthsc.edu</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>31</day><month>7</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>9</month><year>2023</year></pub-date><volume>2</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">444580</issue-id><fpage>301</fpage><lpage>316</lpage><history><date date-type="received"><day>17</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>19</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>03</day><month>09</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-28 19:25:26.160"><day>28</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 the author(s), published by De Gruyter, Berlin/Boston</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>the author(s), published by De Gruyter, Berlin/Boston GmbH, Berlin/Boston</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under the Creative Commons Attribution 4.0 International License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nipt-2-3-nipt-2023-0004.pdf"/><abstract><title>Abstract</title><p>Following the emergence of SARS-CoV-2, various reports suggest that there has been a significant increase in substance abuse due to social distancing and related issues. Several reports have suggested the impact of chronic substance use on individuals&#8217; physiological and psychological health. Therefore, there is a need to know the impact of SARS-CoV-2 on persons with substance use disorders. Individuals with substance use disorders are the most vulnerable groups and are at a high risk of SARS-CoV-2 infection due to their already existing health issues associated with substance use. This review discusses some of the molecular and systemic/organic effects chronic substance use such as alcohol, nicotine, marijuana (cannabis), opioids, methamphetamine, and cocaine have on SARS-CoV-2 infectivity and its potential cause for worsened disease outcomes in persons with substance use disorder. This will provide healthcare providers, public health policies, and researchers with the needed knowledge to address some of the many challenges faced during the Covid-19 pandemic to facilitate treatment strategies for persons with substance use disorders.</p></abstract><kwd-group><title>Keywords</title><kwd>COVID-19</kwd><kwd>molecular effect</kwd><kwd>organ/systemic effect</kwd><kwd>SARS-CoV-2</kwd><kwd>substance use disorder</kwd></kwd-group><funding-group><award-group award-type="grant" id="award-grp1"><funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.13039/100000002">National Institutes of Health</funding-source><award-id>R01DA047178</award-id></award-group></funding-group><counts><table-count count="1"/><ref-count count="163"/><page-count count="16"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="j_nipt-2023-0004_s_001"><title>Introduction</title><p>SARS-CoV-2 is a highly pathogenic member of the coronavirus family [<xref rid="j_nipt-2023-0004_ref_001" ref-type="bibr">1</xref>]. Belonging to the same family, SARS-CoV, and MERS have similar symptoms as SARS-CoV-2 including cough, chest pain, shortness of breath fever, and pneumonia, were not classified as a pandemic due to their lower mortality rate [<xref rid="j_nipt-2023-0004_ref_001" ref-type="bibr">1</xref>]. The World Health Organization (WHO) officially declared SARS-CoV-2 a global pandemic on March 11, 2020, after reporting over 118,000 cases in 114 countries with 4,291 deaths [<xref rid="j_nipt-2023-0004_ref_002" ref-type="bibr">2</xref>].</p><table-wrap position="float" id="j_nipt-2023-0004_tab_001" orientation="portrait"><label>Table 1:</label><caption><p>Summary: substances of abuse and their effect on SAR-CoV-2 pathogenesis.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Drugs of abuse</th><th align="left" rowspan="1" colspan="1">Summary</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Alcohol</td><td rowspan="1" colspan="1">COVID-19 outcomes are worsened in people with alcohol use disorders due to immune system dysfunction, increased risk of aspiration pneumonia, thrombosis, cardiovascular disease, and liver metabolic diseases associated with alcohol use</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Heavy alcohol use significantly decreases lung macrophage, lymphocyte cytokine production and decreases neutrophil recruitment, all of which alter the host&#8217;s immune response to pathogens</td></tr><tr><td rowspan="1" colspan="1">Nicotine</td><td rowspan="1" colspan="1">Increased ACE2 expression in tobacco smokers may result in more cellular entry points for SARS-CoV-2</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Cigarette tar and tobacco smoke decrease lung function and capacity over time by damaging the lining and alveolar sacs of the lungs increasing the risk of respiratory distress from COVID-19</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Tobacco functions as an immunomodulator that can significantly suppress the immune system by reducing antibody responses and T-cell proliferation, thereby increasing the susceptibility of tobacco users to acute viral infections</td></tr><tr><td rowspan="1" colspan="1">Marijuana</td><td rowspan="1" colspan="1">Marijuana use increases the likelihood of cough, sputum production, wheezing, chest sounds, chronic bronchitis, and cardiovascular complications</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Marijuana can modulate the immune system by acting on T-cells, B cells, macrophages, and lymphocyte receptors, decreasing immunity and increasing susceptibility to viral infections such as COVID-19</td></tr><tr><td rowspan="1" colspan="1">Opioids</td><td rowspan="1" colspan="1">COVID-19 and opioid exposure may have similar disease outcomes including respiratory depression and hypoxia, and the combination of these two could lead to an aggravated complication in neuro-immunity and respiratory depression</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Acute kidney injury from opioid use is commonly accompanied by respiratory failure, which is associated with poor COVID outcomes including ventilation, renal replacement therapy, and death</td></tr><tr><td rowspan="1" colspan="1">Methamphetamine</td><td rowspan="1" colspan="1">Free radical formation from methamphetamine use causes pulmonary toxicity which impairs lung function</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Cognitive impairments caused by a loss of dopamine and serotonin from chronic methamphetamine use could contribute to the mood and sleep disorders seen in those suffering from long COVID</td></tr><tr><td rowspan="1" colspan="1">Cocaine</td><td rowspan="1" colspan="1">Patients with COVID-19 and cocaine use disorders experience an increase of pro-inflammatory and decreased anti-inflammatory cytokines</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Cocaine use affects many organs throughout the body, including the cardiovascular, CNS, and respiratory systems, causing a higher risk of susceptibility</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">The synergistic effect of infection from SAR-COV-2 and the consumption of cocaine is prothrombic, resulting in a hypercoagulable state, and increasing the risk of myocardial infarction</td></tr><tr><td rowspan="1" colspan="1">Cannabinoids</td><td rowspan="1" colspan="1">Cannabidolic acid and cannabigerolic acid, may block infection of human cells by SARS-CoV-2 expressing the spike protein</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">CBD can reduce proinflammatory cytokines IL-2, IL-6, IL-1&#945; and &#946;, interferon gamma, and inducible protein-10 that have been associated with SARS-CoV-2</td></tr></tbody></table></table-wrap><p>SARS-CoV-2 can infect all immune cells (monocyte, dendritic cells, macrophages, lymphocytes) leading to hypercytokinemia (cytokine storm) resulting from immune dysregulation [<xref rid="j_nipt-2023-0004_ref_003" ref-type="bibr">3</xref>&#8211;<xref rid="j_nipt-2023-0004_ref_007" ref-type="bibr">7</xref>]. The excessive cytokine release in the presence of SARS-CoV-2 in other parts of the body especially the lungs, leads to acute respiratory distress syndrome [<xref rid="j_nipt-2023-0004_ref_008" ref-type="bibr">8</xref>]. Not only does SARS-CoV-2 affect the lungs, but researchers and clinicians have reported implications in some major organs and systems including the central nervous system, heart, liver, kidney, gastrointestinal tract, and blood vessels [<xref rid="j_nipt-2023-0004_ref_009" ref-type="bibr">9</xref>&#8211;<xref rid="j_nipt-2023-0004_ref_011" ref-type="bibr">11</xref>].</p><p>The COVID-19 pandemic has not only impacted the health of people but health care systems and policies around the world [<xref rid="j_nipt-2023-0004_ref_012" ref-type="bibr">12</xref>, <xref rid="j_nipt-2023-0004_ref_013" ref-type="bibr">13</xref>]. These impacts range from social distancing, lockdowns, financial constraints, etc., in some way, impacted the physiological and mental well-being of people [<xref rid="j_nipt-2023-0004_ref_013" ref-type="bibr">13</xref>, <xref rid="j_nipt-2023-0004_ref_014" ref-type="bibr">14</xref>]. Approximately 45&#8239;% of US adults have expressed stress and worry over the virus, which has impacted their mental health negatively [<xref rid="j_nipt-2023-0004_ref_015" ref-type="bibr">15</xref>]. These factors related to the pandemic considerably impacted the consumption of substances, especially in people with substance use disorders which may affect their health negatively [<xref rid="j_nipt-2023-0004_ref_016" ref-type="bibr">16</xref>].</p><p>A recent report by the Center for Disease Control and Prevention (CDC) suggests that the number of deathsfrom substance overdose in the United State is over 932,000 since 1999 [<xref rid="j_nipt-2023-0004_ref_017" ref-type="bibr">17</xref>]. The most common substances abused in the US include alcohol, opioids (prescription or illicit), marijuana, tobacco (nicotine), cocaine, and methamphetamine [<xref rid="j_nipt-2023-0004_ref_018" ref-type="bibr">18</xref>]. The increase in distress and anxiety associated with the COVID-19 pandemic brought about a general increase in cannabis consumption (6&#8211;8&#8239;% in adults), alcohol consumption (10&#8211;18&#8239;%), and other substances (3&#8239;%) [<xref rid="j_nipt-2023-0004_ref_019" ref-type="bibr">19</xref>]. Data suggest that people with prior substance use disorders (SUD) increased their consumption during the pandemic while others consumed substances in order to cope with the social impacts the pandemic brought [<xref rid="j_nipt-2023-0004_ref_019" ref-type="bibr">19</xref>].</p><p>People with substance use disorders are often subjected to chronic illnesses such as COPD, arrhythmias, myocardial infarction, hypertension, diabetes, and cardiac insufficiency [<xref rid="j_nipt-2023-0004_ref_020" ref-type="bibr">20</xref>&#8211;<xref rid="j_nipt-2023-0004_ref_022" ref-type="bibr">22</xref>], which are all risk factors associated with COVID-19 infections. It is probable that individuals with substance use disorders have worsened disease outcomes [<xref rid="j_nipt-2023-0004_ref_023" ref-type="bibr">23</xref>&#8211;<xref rid="j_nipt-2023-0004_ref_025" ref-type="bibr">25</xref>].</p><p>Currently, there is little information regarding the direct effect SARS-CoV-2 has on individuals with substance use disorder in terms of the individual&#8217;s organs and systems. Therefore, in this review, we discuss the molecular and systemic/organic effects chronic substance use such as alcohol, nicotine, marijuana (cannabis), opioids, methamphetamine, and cocaine have on SARS-CoV-2 infectivity, and how SARS-CoV-2 may worsen disease outcomes in persons with substance use disorder based on the limited published articles <xref rid="j_nipt-2023-0004_tab_001" ref-type="table">Table 1</xref>.</p></sec><sec id="j_nipt-2023-0004_s_002"><title>Effects of alcohol use on SARS-CoV-2</title><p>The surge of the COVID-19 pandemic resulted in disruption to health care and an increase in alcohol use, resulting in serious health repercussions in people with alcohol use disorders (AUD) [<xref rid="j_nipt-2023-0004_ref_026" ref-type="bibr">26</xref>, <xref rid="j_nipt-2023-0004_ref_027" ref-type="bibr">27</xref>]. Worsened disease outcomes were observed, especially in people with alcohol-associated liver disease [<xref rid="j_nipt-2023-0004_ref_016" ref-type="bibr">16</xref>]. This section of the paper discusses what happens at the molecular and organic/systemic levels when people with alcohol use disorders are infected with SARS-CoV-2.</p><sec id="j_nipt-2023-0004_s_002_s_001"><title>Molecular effects</title><p>Excessive alcohol consumption can cause immune system impairment, liver cirrhosis, and other complications that can be associated with worsened outcomes in respiratory disorders [<xref rid="j_nipt-2023-0004_ref_028" ref-type="bibr">28</xref>&#8211;<xref rid="j_nipt-2023-0004_ref_030" ref-type="bibr">30</xref>]. As a result, severe and worsened progression of COVID-19 in individuals with alcohol use disorders was hypothesized by Dubey et&#160;al. and Muhammad et&#160;al. [<xref rid="j_nipt-2023-0004_ref_031" ref-type="bibr">31</xref>, <xref rid="j_nipt-2023-0004_ref_032" ref-type="bibr">32</xref>]. Dubey et&#160;al. suggested that there may be a synergistic worsening of COVID-19 outcomes in people with alcohol use disorders due to immune system dysfunction, increased risk of aspiration pneumonia, thrombosis, cardiovascular disease, and liver metabolic diseases associated with alcohol use [<xref rid="j_nipt-2023-0004_ref_031" ref-type="bibr">31</xref>]. Muhammed et&#160;al. reported upregulation of proinflammatory markers CCR2, DPP9, HSPAIL, TYK2, OAS1, ACE2, and TMPRSS2 in brain tissues of alcohol use disorder patients who died while hospitalized with severe COVID-19 outcomes as compared to non-alcohol using patients [<xref rid="j_nipt-2023-0004_ref_032" ref-type="bibr">32</xref>]. In this report, they observed an upregulation of HSPAIL, a gene involved in host epigenetic regulation that leads to increased SARS-CoV-2 replication and the OAS1 gene associated with viral infection susceptibility. OAS1 and HSPAIL are genes associated with increased receptiveness to viral infections while CCR2 and TYK2 are also important drivers of inflammation. Based on these observations, they hypothesized that individuals with alcohol use disorders are at increased risk of developing severe neurological complications when exposed to SARS-CoV-2 compared to those without alcohol use disorder [<xref rid="j_nipt-2023-0004_ref_032" ref-type="bibr">32</xref>, <xref rid="j_nipt-2023-0004_ref_033" ref-type="bibr">33</xref>]. Friske et&#160;al. reported upregulation of ACE2 and TMPRSS2, the entry points of SARS-CoV-2, and the anti-inflammatory gene MAS, which is activated upon infection in the lungs of chronic alcohol-exposed rat models [<xref rid="j_nipt-2023-0004_ref_034" ref-type="bibr">34</xref>]. They also reported upregulation of ACE2 in other organs including the liver, heart, kidney, ileum, and brain in the alcohol-exposed group. Although upregulation of the entry point for SARS-CoV-2 may lead to increased infectivity and reduced immunity to viral infectivity in these organs, the authors did not assess the potential for worsened outcomes [<xref rid="j_nipt-2023-0004_ref_034" ref-type="bibr">34</xref>&#8211;<xref rid="j_nipt-2023-0004_ref_037" ref-type="bibr">37</xref>]. Huang et&#160;al. reported a Network Meta-Analysis suggesting that ethanol exposure may increase SARS-CoV-2-induced systemic inflammation by altering important inflammation mediators [<xref rid="j_nipt-2023-0004_ref_038" ref-type="bibr">38</xref>]. This report suggests that ethanol increases the effect of SARS-CoV-2 infection on cellular metabolism, the hepatic fibrosis signaling pathway, inflammation, cellular homeostasis, and neuroinflammation. This was observed following increased activity of cytokines (IL-6, TNF, IL-1b), transcription factors including STAT and JUN, and the inhibition of anti-inflammatory mediators&#8217; activity such as glucocorticoid receptors [<xref rid="j_nipt-2023-0004_ref_038" ref-type="bibr">38</xref>].</p></sec><sec id="j_nipt-2023-0004_s_002_s_002"><title>Systemic/organ effects</title><p>As previously stated, long-term use of alcohol can be extremely detrimental to an individual&#8217;s health [<xref rid="j_nipt-2023-0004_ref_028" ref-type="bibr">28</xref>]. Alcohol use is one of the leading causes of acquired immunity disorders and can be linked to being a major risk factor for SARS-COV-2 contraction and severity [<xref rid="j_nipt-2023-0004_ref_039" ref-type="bibr">39</xref>, <xref rid="j_nipt-2023-0004_ref_040" ref-type="bibr">40</xref>]. Healthy lungs possess protective mechanisms such as alveolar macrophages, which trigger an immune response and mediate the influx of neutrophils into the lungs [<xref rid="j_nipt-2023-0004_ref_030" ref-type="bibr">30</xref>]. This process plays a pivotal role in the clearance of viral pathogens. Heavy alcohol use significantly decreases lung macrophage and lymphocyte cytokine production and decreases neutrophil recruitment, all of which alter the host immune response [<xref rid="j_nipt-2023-0004_ref_030" ref-type="bibr">30</xref>]. This causes damage to the alveolar barrier, altering the integrity and making it more permeable to viruses [<xref rid="j_nipt-2023-0004_ref_041" ref-type="bibr">41</xref>]. Phagocytosis of viruses is also impaired in heavy alcohol users by depleting glutathione stores in the lungs [<xref rid="j_nipt-2023-0004_ref_028" ref-type="bibr">28</xref>]. This results in increased susceptibility to oxidative stress due to impaired detoxification and clearance of toxic oxidants, increasing the risk of acute respiratory distress syndrome (ARDS) [<xref rid="j_nipt-2023-0004_ref_028" ref-type="bibr">28</xref>]. Furthermore, alcohol alters the flora in the oropharynx, facilitating the colonization of Gram-negative bacteria. Alcohol causes cough and gag reflex suppression, which increases the risk of bacteria being aspirated. Collectively, these mechanisms contribute to respiratory system decline, increasing the risk for SARS-CoV-2 [<xref rid="j_nipt-2023-0004_ref_030" ref-type="bibr">30</xref>, <xref rid="j_nipt-2023-0004_ref_042" ref-type="bibr">42</xref>]. SARS-CoV-2 produces a strong inflammatory response, often leading to hypercytokinemia [<xref rid="j_nipt-2023-0004_ref_028" ref-type="bibr">28</xref>]. This hyperactive inflammatory response is one of the leading causes of systemic organ failure in SARS-CoV-2 [<xref rid="j_nipt-2023-0004_ref_042" ref-type="bibr">42</xref>]. Heavy alcohol users have higher baseline concentrations of pro-inflammatory markers and lower levels of essential micronutrients. This predisposes them to poorer prognoses and more severe exacerbations of inflammatory diseases, like SARS-COV-2 [<xref rid="j_nipt-2023-0004_ref_040" ref-type="bibr">40</xref>, <xref rid="j_nipt-2023-0004_ref_043" ref-type="bibr">43</xref>].</p><p>Although these findings suggest a possible worsened outcome in persons with AUD it does not necessarily support a direct worsened disease outcome in these individuals. Research and experimental data must be published to indicate the direct association between SARS-CoV-2 and alcohol use disorder causing worsened disease severity.</p></sec></sec><sec id="j_nipt-2023-0004_s_003"><title>Effect of nicotine use on SARS-CoV-2</title><p>Nicotine, while one of the leading causes of preventable death in the United States, also saw an increasing trend of use during the pandemic [<xref rid="j_nipt-2023-0004_ref_044" ref-type="bibr">44</xref>]. The addictive use of nicotine is associated with increased morbidity, often leading to cancer and death. Moreover, SARS-CoV-2 can synergistically deteriorate lung functions further when nicotine is abused in persons with nicotine use disorders [<xref rid="j_nipt-2023-0004_ref_045" ref-type="bibr">45</xref>]. Due to this reason, it is necessary to examine the effect nicotine use disorders have on SARS-CoV-2 at both the molecular and organic levels.</p><sec id="j_nipt-2023-0004_s_003_s_001"><title>Molecular effects</title><p>Since the emergence of SARS-CoV-2 in 2019 many diverse factors have been linked to the severity of the disease among tobacco smokers since they both impact the respiratory system [<xref rid="j_nipt-2023-0004_ref_045" ref-type="bibr">45</xref>&#8211;<xref rid="j_nipt-2023-0004_ref_047" ref-type="bibr">47</xref>]. Over the years, studies on the effect of tobacco smoking have established the fact that it compromises the immune and respiratory systems [<xref rid="j_nipt-2023-0004_ref_048" ref-type="bibr">48</xref>, <xref rid="j_nipt-2023-0004_ref_049" ref-type="bibr">49</xref>]. However, the effect of tobacco smoking on SARS-CoV-2 infection and its impact on COVID-19 remains surprisingly controversial [<xref rid="j_nipt-2023-0004_ref_050" ref-type="bibr">50</xref>]. The major entry receptor of SARS-CoV-2 to host cells is via the human angiotensin converting enzyme-2 [<xref rid="j_nipt-2023-0004_ref_004" ref-type="bibr">4</xref>, <xref rid="j_nipt-2023-0004_ref_051" ref-type="bibr">51</xref>, <xref rid="j_nipt-2023-0004_ref_052" ref-type="bibr">52</xref>]. Overexpression of ACE2 in lower respiratory tract epithelial cells has been observed in current tobacco smokers due to nicotine induced ACE2 expression [<xref rid="j_nipt-2023-0004_ref_052" ref-type="bibr">52</xref>&#8211;<xref rid="j_nipt-2023-0004_ref_055" ref-type="bibr">55</xref>]. Increased ACE2 expression in tobacco smokers may result in more cellular entry points for SARS-CoV-2 [<xref rid="j_nipt-2023-0004_ref_055" ref-type="bibr">55</xref>]. Maggi et&#160;al. reported a direct link between nicotine exposure to worsened outcomes in SARS-CoV-2 infection [<xref rid="j_nipt-2023-0004_ref_056" ref-type="bibr">56</xref>]. In this report, they observed a rapid and long-lasting increase in protein and gene expression of the ACE2 receptor when they exposed the human pulmonary adenocarcinoma epithelial cell line A549, which naturally expresses low levels of ACE2, to nicotine [<xref rid="j_nipt-2023-0004_ref_056" ref-type="bibr">56</xref>]. Specifically, they noticed that exposure to nicotine in this cell line not only upregulated ACE2 expression [<xref rid="j_nipt-2023-0004_ref_054" ref-type="bibr">54</xref>, <xref rid="j_nipt-2023-0004_ref_057" ref-type="bibr">57</xref>] but also upregulated &#945;7-nAChR expression via the activation of MAPK/ERK, induced cell proliferation, and cell migration [<xref rid="j_nipt-2023-0004_ref_058" ref-type="bibr">58</xref>, <xref rid="j_nipt-2023-0004_ref_059" ref-type="bibr">59</xref>]. In terms of its effect on SARS-CoV-2, it increases pathogen replication and transcription of viral proteins [<xref rid="j_nipt-2023-0004_ref_059" ref-type="bibr">59</xref>], thereby increasing the cytopathic effect of SARS-CoV-2. These findings suggest that nicotine increases SARS-CoV-2 infectivity [<xref rid="j_nipt-2023-0004_ref_056" ref-type="bibr">56</xref>, <xref rid="j_nipt-2023-0004_ref_060" ref-type="bibr">60</xref>]. The idea that nicotine may present a cause for worsened SARS-CoV-2 infection was investigated in another study by looking at the mechanism involved in increased infectivity [<xref rid="j_nipt-2023-0004_ref_057" ref-type="bibr">57</xref>]. In a work presented by Lupacchini et&#160;al., they observed that through the induction of the &#945;7-nAChR under conditions that mimic human smokers, nicotine increased cell viability, upregulated phospho-p38, and overexpressed Ki67, EGFR, and pEGFR [<xref rid="j_nipt-2023-0004_ref_058" ref-type="bibr">58</xref>]. They also observed a reduction in ATP [<xref rid="j_nipt-2023-0004_ref_061" ref-type="bibr">61</xref>], p-53, and phospho p53 levels [<xref rid="j_nipt-2023-0004_ref_062" ref-type="bibr">62</xref>], increases in Ca2+ basal concentration [<xref rid="j_nipt-2023-0004_ref_063" ref-type="bibr">63</xref>], and an increase in VEGF. All these findings suggest the involvement of nicotine in the upregulation and severity of SARS-CoV-2 infection [<xref rid="j_nipt-2023-0004_ref_058" ref-type="bibr">58</xref>].</p><p>However, some reports suggest that nicotine may reduce inflammation via its interaction with the nAChR, and nicotine itself may prevent the attachment of SARS-CoV-2 to ACE2, therefore protecting host cells against SARS-CoV-2 infection [<xref rid="j_nipt-2023-0004_ref_064" ref-type="bibr">64</xref>&#8211;<xref rid="j_nipt-2023-0004_ref_066" ref-type="bibr">66</xref>]. Farsalinos et&#160;al. performed a study based on molecular modeling and docking (<italic toggle="yes">in silico</italic>) where they identified an interaction between nAChRs and a toxin-like sequence in the receptor-binding domain of SARS-CoV-2 spike glycoprotein [<xref rid="j_nipt-2023-0004_ref_066" ref-type="bibr">66</xref>]. They observed that the interaction between the glycoprotein of SARS-CoV-2 and nAChRs may lead to a cytokine storm and a hyper-immune response resulting from crosstalk between the nicotine cholinergic system (NCS) and the cholinergic anti-inflammatory pathway. Based on clinical findings that suggest a low rate of hospitalization among tobacco smokers in COVID-19 hospitalized patients, but higher rates of adverse effects when hospitalized, they hypothesized that nicotine and other cholinergic agonists can restore the NCS dysregulation and the function of the cholinergic anti-inflammatory pathway [<xref rid="j_nipt-2023-0004_ref_066" ref-type="bibr">66</xref>, <xref rid="j_nipt-2023-0004_ref_067" ref-type="bibr">67</xref>]. Although this study shows that nicotine may help restore NCS dysregulation caused by SARS-CoV-2, this study was solely theoretical with no <italic toggle="yes">in vivo</italic> or <italic toggle="yes">in vitro</italic> experiment to confirm the interaction between nAChRs and SARS-CoV-2 [<xref rid="j_nipt-2023-0004_ref_065" ref-type="bibr">65</xref>, <xref rid="j_nipt-2023-0004_ref_067" ref-type="bibr">67</xref>, <xref rid="j_nipt-2023-0004_ref_068" ref-type="bibr">68</xref>].</p></sec><sec id="j_nipt-2023-0004_s_003_s_002"><title>Systemic/organ effects</title><p>Nicotine has well-known adverse effects on organs throughout the body, particularly the lungs, which can impact respiratory and immune function [<xref rid="j_nipt-2023-0004_ref_069" ref-type="bibr">69</xref>]. Damage to these organs can result in an increased risk of SARS-CoV-2 [<xref rid="j_nipt-2023-0004_ref_070" ref-type="bibr">70</xref>]. Studies have focused attention on the ACE2 receptor, and while some studies have suggested that tobacco may be protective against SARS-CoV-2, other studies have shown different results [<xref rid="j_nipt-2023-0004_ref_069" ref-type="bibr">69</xref>, <xref rid="j_nipt-2023-0004_ref_071" ref-type="bibr">71</xref>]. Previous studies suggested that nicotine upregulates the ACE/angiotensin II (ANG II)/ANG II type 1 receptor axis while downregulating ACE2, resulting in SARS-COV-2 protection [<xref rid="j_nipt-2023-0004_ref_071" ref-type="bibr">71</xref>, <xref rid="j_nipt-2023-0004_ref_072" ref-type="bibr">72</xref>]. However, more recent studies have shown that tobacco smokers have an increased expression of ACE2 in bronchial epithelial cells in the respiratory tract, which may promote SARS-COV-2 entry and proliferation through co-expression with nicotinic receptors [<xref rid="j_nipt-2023-0004_ref_069" ref-type="bibr">69</xref>, <xref rid="j_nipt-2023-0004_ref_070" ref-type="bibr">70</xref>]. Cigarette tar, a byproduct of tobacco combustion, can also induce lung damage by damaging cilia in the lungs [<xref rid="j_nipt-2023-0004_ref_070" ref-type="bibr">70</xref>]. This reduces the surface area between capillaries, decreasing the capacity of the arteries to transport oxygenated blood. With low blood oxygen levels being a strong predictor of poor COVID-19 outcomes, this closely ties cigarette use with more severe COVID-19 symptoms [<xref rid="j_nipt-2023-0004_ref_073" ref-type="bibr">73</xref>]. Tobacco smoke is known to activate and modify immune activity in the lungs, which can lead to the development of inflammatory lung diseases, including, COPD, asthma, and other lung diseases, putting tobacco users at a higher risk for contracting infections [<xref rid="j_nipt-2023-0004_ref_071" ref-type="bibr">71</xref>]. Lung function abnormalities demonstrated by smokers when compared with lifelong nonsmokers include reduced forced expiratory volume in 1&#8239;s (FEV1), peak expiratory flow (PEF), and the ratio of FEV1 to forced vital capacity (FVC, FEV1/FVC) [<xref rid="j_nipt-2023-0004_ref_074" ref-type="bibr">74</xref>]. Individuals with COPD also have deficiencies in these lung function tests, specifically spirometry [<xref rid="j_nipt-2023-0004_ref_075" ref-type="bibr">75</xref>]. COPD is the single greatest predictor of comorbidity for severe COVID-19 leading to ICU admission, supporting the idea that smoking increases the risk for viral infections, such as SARS-COV-2 [<xref rid="j_nipt-2023-0004_ref_075" ref-type="bibr">75</xref>]. Additionally, tobacco functions as an immunomodulator that can significantly suppress the immune system by reducing antibody responses and T-cell proliferation, thereby increasing the susceptibility of tobacco users to acute viral infections [<xref rid="j_nipt-2023-0004_ref_070" ref-type="bibr">70</xref>]. Immune suppression due to nicotine, particularly through the decrease in CD8+ T-cells that facilitate rapid resolution of acute viral infections, increases the susceptibility of smokers to viral infections [<xref rid="j_nipt-2023-0004_ref_076" ref-type="bibr">76</xref>]. Multiple components of tobacco decrease immune function, and individuals who use tobacco are at an increased risk of susceptibility to infection with SARS-CoV-2.</p><p>The findings observed through published articles and data suggest detrimental and potentially beneficial effects of nicotine use in COVID-19. However, this confirms the need for more substantial evidence to support a worsened disease outcome of SARS-CoV-2 in people with nicotine use disorders.</p></sec></sec><sec id="j_nipt-2023-0004_s_004"><title>Effect of marijuana (cannabis) use on SARS-CoV-2</title><p>In 2018, an estimated population of 192 million people used cannabis worldwide [<xref rid="j_nipt-2023-0004_ref_077" ref-type="bibr">77</xref>]. This makes cannabis the third most-used substance following alcohol and tobacco [<xref rid="j_nipt-2023-0004_ref_077" ref-type="bibr">77</xref>]. Prolonged usage of marijuana which can be associated with impaired respiratory function, cardiovascular diseases, and adverse psychological and mental health issues must be reviewed when discussing the impact of COVID-19 on persons with cannabis use disorder (CUD) since SARS-CoV-2 also impacts these systems [<xref rid="j_nipt-2023-0004_ref_078" ref-type="bibr">78</xref>].</p><sec id="j_nipt-2023-0004_s_004_s_001"><title>Molecular effects</title><p>Recent data suggests increased use of cannabis during the COVID-19 lockdown period [<xref rid="j_nipt-2023-0004_ref_079" ref-type="bibr">79</xref>]. Unlike alcohol and nicotine abuse, where experimental models have been utilized to see the impact of the drug on the SARS-CoV-2 infection at the molecular level, no <italic toggle="yes">in vitro</italic> experiments have been done on marijuana use at the time of this review. However, there have been reports suggesting the possible increased susceptibility to SARS-CoV-2 in individuals with cannabis use disorders based on the cellular or molecular complications associated with cannabis use [<xref rid="j_nipt-2023-0004_ref_076" ref-type="bibr">76</xref>, <xref rid="j_nipt-2023-0004_ref_080" ref-type="bibr">80</xref>], [<xref rid="j_nipt-2023-0004_ref_081" ref-type="bibr">81</xref>], [<xref rid="j_nipt-2023-0004_ref_082" ref-type="bibr">82</xref>]. Marijuana has previously been found to be an immunosuppressant that suppresses the activation of proinflammatory cytokines such as IL-6, IL-1&#945;, TNF&#945;, and IL-1&#946;, as well as T lymphocytes, which are essential mediators in the immune response to pathogens [<xref rid="j_nipt-2023-0004_ref_080" ref-type="bibr">80</xref>]. Due to the downregulation of these key mediators, host cells may be more susceptible to viral pathogens such as SARS-CoV-2 [<xref rid="j_nipt-2023-0004_ref_076" ref-type="bibr">76</xref>]. As an immunomodulator, marijuana works by modulating immune function and the brain [<xref rid="j_nipt-2023-0004_ref_076" ref-type="bibr">76</xref>, <xref rid="j_nipt-2023-0004_ref_080" ref-type="bibr">80</xref>]. Chronic obstructive pulmonary disease, is a major risk factor for complications associated with worsened COVID-19 outcomes in tobacco smokers [<xref rid="j_nipt-2023-0004_ref_081" ref-type="bibr">81</xref>], has also been suggested to have an evidential risk factor linked to marijuana smokers [<xref rid="j_nipt-2023-0004_ref_082" ref-type="bibr">82</xref>].</p><p>Other studies of cannabis products on SARS-CoV-2 suggest a potential therapeutic effect [<xref rid="j_nipt-2023-0004_ref_083" ref-type="bibr">83</xref>&#8211;<xref rid="j_nipt-2023-0004_ref_088" ref-type="bibr">88</xref>]. The downregulation of COVID-19 associated proinflammatory cytokines (cytokine storm) has been reported as an aspect to explore in the treatment of the disease [<xref rid="j_nipt-2023-0004_ref_089" ref-type="bibr">89</xref>&#8211;<xref rid="j_nipt-2023-0004_ref_092" ref-type="bibr">92</xref>]. Many reports have suggested a decrease in proinflammatory cytokines and chemokines, downregulation of inflammatory pathways associated genes, inhibition of SARS-CoV-2 targeted genes, and inhibition of viral replication when cannabis or its related products were experimentally used in <italic toggle="yes">in vitro</italic> analysis [<xref rid="j_nipt-2023-0004_ref_086" ref-type="bibr">86</xref>, <xref rid="j_nipt-2023-0004_ref_090" ref-type="bibr">90</xref>, <xref rid="j_nipt-2023-0004_ref_093" ref-type="bibr">93</xref>], [<xref rid="j_nipt-2023-0004_ref_094" ref-type="bibr">94</xref>], [<xref rid="j_nipt-2023-0004_ref_095" ref-type="bibr">95</xref>], [<xref rid="j_nipt-2023-0004_ref_096" ref-type="bibr">96</xref>]. IL-6 and TNF&#945;, key mediators in a cytokine storm, were reported to be downregulated in a WI-38 lung fibroblast cell line model [<xref rid="j_nipt-2023-0004_ref_097" ref-type="bibr">97</xref>]. They also saw downregulation of COX2, CCL2, and other cytokines involved in inflammatory pathways [<xref rid="j_nipt-2023-0004_ref_097" ref-type="bibr">97</xref>]. Similarly, Anil et&#160;al. reported a reduction of IL-6 and IL-8, prominent cytokines involved in cytokine storms in severe COVID-19 patients [<xref rid="j_nipt-2023-0004_ref_098" ref-type="bibr">98</xref>]. They reported an altered inflammatory cytokine response [<xref rid="j_nipt-2023-0004_ref_099" ref-type="bibr">99</xref>] after a 4-h exposure of 5&#8239;&#956;g/mL cannabis extract to an alveolar epithelial (A549) cell line, suggesting an anti-inflammatory response to cannabis [<xref rid="j_nipt-2023-0004_ref_098" ref-type="bibr">98</xref>, <xref rid="j_nipt-2023-0004_ref_100" ref-type="bibr">100</xref>, <xref rid="j_nipt-2023-0004_ref_101" ref-type="bibr">101</xref>]. In addition to the response observed for IL-6 and IL-8, inflammatory chemokines CCL2 and CCL7 which are found in the bronchoalveolar fluid of severe COVID-19 patients [<xref rid="j_nipt-2023-0004_ref_102" ref-type="bibr">102</xref>] were also observed to downregulate after 6&#8239;h treatment of alveolar epithelial with cannabis [<xref rid="j_nipt-2023-0004_ref_098" ref-type="bibr">98</xref>] and ACE2 expression was also found to be downregulated after 4&#8211;6&#8239;h post cannabis treatment [<xref rid="j_nipt-2023-0004_ref_098" ref-type="bibr">98</xref>, <xref rid="j_nipt-2023-0004_ref_103" ref-type="bibr">103</xref>]. Treatment with Cannabis Sativa extract also increased the expression of CD36 and Fc&#947;RII type II receptor, which are involved in the initiation of macrophage phagocytosis [<xref rid="j_nipt-2023-0004_ref_104" ref-type="bibr">104</xref>, <xref rid="j_nipt-2023-0004_ref_105" ref-type="bibr">105</xref>], suggesting that cannabis may aid in the clearance of respiratory viruses including SARS-CoV-2 at the initial phase of infection [<xref rid="j_nipt-2023-0004_ref_098" ref-type="bibr">98</xref>]. The downregulation of ACE2 expression and the serine protease TMPRSS2, which serves as a critical entry point for SARS-CoV-2 were seen in a report by Wang et&#160;al. [<xref rid="j_nipt-2023-0004_ref_094" ref-type="bibr">94</xref>]. Cannabidiol has also been shown to inhibit SARS-CoV-2 viral gene expression and replication <italic toggle="yes">in vitro</italic> in lung epithelial cells and upregulate antiviral signaling pathway induced by interferon expression [<xref rid="j_nipt-2023-0004_ref_084" ref-type="bibr">84</xref>, <xref rid="j_nipt-2023-0004_ref_085" ref-type="bibr">85</xref>, <xref rid="j_nipt-2023-0004_ref_087" ref-type="bibr">87</xref>].</p><p>Although some cannabis products may have potential therapeutic properties against SARS-CoV-2, there are side effects that need to be regarded such as a risk of drug interactions with other COVID-19 drugs, and the route of drug administration like vaping which can be detrimental to health [<xref rid="j_nipt-2023-0004_ref_090" ref-type="bibr">90</xref>].</p></sec><sec id="j_nipt-2023-0004_s_004_s_002"><title>Systemic/organ effects</title><p>During the SARS-CoV-2 pandemic, there has been a surge in marijuana use [<xref rid="j_nipt-2023-0004_ref_106" ref-type="bibr">106</xref>]. While medicinal marijuana may have positive health effects on COVID-19, other studies suggest that marijuana use may result in a higher risk of SARS-CoV-2 acquisition with more severe symptoms [<xref rid="j_nipt-2023-0004_ref_107" ref-type="bibr">107</xref>]. Specifically, chronic marijuana use is associated with immunosuppression, cardiovascular deficiencies, and respiratory tract dysfunction, all of which increase the risk of SARS-CoV-2 [<xref rid="j_nipt-2023-0004_ref_108" ref-type="bibr">108</xref>, <xref rid="j_nipt-2023-0004_ref_109" ref-type="bibr">109</xref>]. Although individuals who use marijuana have a lower odds ratio of contracting SARS-CoV-2 than opioids, tobacco, and alcohol, the risk is five times greater than in people who do not use substances of abuse [<xref rid="j_nipt-2023-0004_ref_107" ref-type="bibr">107</xref>]. Studies have shown that marijuana and other psychoactive substances modulate the immune system by acting on T-cell, B-cell, macrophage, and lymphocyte receptors, which decrease immunity and increase susceptibility to viral infections [<xref rid="j_nipt-2023-0004_ref_110" ref-type="bibr">110</xref>]. Marijuana has been shown to alter the hypothalamic-pituitary-adrenal (HPA) axis, which plays a significant role in orchestrating immune responses. HPA axis impairment decreases the regulation of pathogens [<xref rid="j_nipt-2023-0004_ref_111" ref-type="bibr">111</xref>]. Additionally, marijuana inhibits T-cell activation by increasing immunosuppressive cytokine production and decreasing the expression of T-cell activating cytokines, which decreases the clearance of pathogens. Thus, marijuana dependent immunosuppression of macrophages, T-cells, and B-cells puts individuals at greater risk of contracting SARS-CoV-2 [<xref rid="j_nipt-2023-0004_ref_109" ref-type="bibr">109</xref>]. With the increasing use of cannabis throughout the population, there are more studies associating cannabis use with cardiovascular complications including acute coronary syndrome, lethal cardiac arrhythmias, and ischemic stroke [<xref rid="j_nipt-2023-0004_ref_107" ref-type="bibr">107</xref>]. Because preexisting cardiovascular disease is a strong predictor of poor disease outcomes in SARS-CoV-2, marijuana use may also be associated with a higher SARS-CoV-2 risk [<xref rid="j_nipt-2023-0004_ref_112" ref-type="bibr">112</xref>]. Furthermore, cannabis use has been reported to increase the risk of ischemic stroke, particularly in healthy young patients. This is a reason for concern given increased use of cannabis in adolescents [<xref rid="j_nipt-2023-0004_ref_113" ref-type="bibr">113</xref>]. Because marijuana users have an increased risk of developing arterial thromboses at baseline, cannabis use may result in worsened outcomes in SARS-CoV-2 despite optimal treatment [<xref rid="j_nipt-2023-0004_ref_114" ref-type="bibr">114</xref>]. Marijuana is used most commonly via inhalation, resulting in similar effects on the lungs as tobacco, including increased cough, sputum production, hyper-inflammation, and upper lobe emphysematous changes [<xref rid="j_nipt-2023-0004_ref_108" ref-type="bibr">108</xref>]. Although it does not seem to contribute to the development of chronic obstructive pulmonary dysfunction (COPD), there is mixed data about the effects that smoking marijuana has on pulmonary function [<xref rid="j_nipt-2023-0004_ref_108" ref-type="bibr">108</xref>]. Data shows that respiratory symptoms are uniformly increased in marijuana smokers. In the NHANES III study, both marijuana and tobacco smokers had an increased likelihood of cough, sputum production, wheezing, chest sounds, and chronic bronchitis [<xref rid="j_nipt-2023-0004_ref_115" ref-type="bibr">115</xref>]. This indicates that smoking marijuana compromises the respiratory system. Therefore, it is likely that since SARS-CoV-2 primarily targets the respiratory system, marijuana smoke will increase SARS-CoV-2 risk.</p><p>In terms of the beneficial and detrimental effects, marijuana and nicotine behave similarly as both are inhaled substances. Nonetheless cannabis use disorder could potentially pose a risk factor in COVID-19 patients since long term use of marijuana has increased the morbidity rate. Evidently, more experimental research needs to be conducted to associate marijuana use with the potential for worsened disease outcomes in these individuals.</p></sec></sec><sec id="j_nipt-2023-0004_s_005"><title>Effect of opioid use on SARS-CoV-2</title><p>A global study conducted in 2016 indicates that about 26.8 million people live with opioid use disorders (OUD) of which more than 100,000 die annually including over 47,000 people in the USA [<xref rid="j_nipt-2023-0004_ref_116" ref-type="bibr">116</xref>]. Similar to other substances of abuse, dependence on opioids can be detrimental to an individual&#8217;s health. Therefore, a study of the molecular and organ impacts SARS-CoV-2 can have on these vulnerable individuals needs to be discussed.</p><sec id="j_nipt-2023-0004_s_005_s_001"><title>Molecular effects</title><p>Research has shown an increased risk of severe COVID-19 associated with opioid use [<xref rid="j_nipt-2023-0004_ref_117" ref-type="bibr">117</xref>&#8211;<xref rid="j_nipt-2023-0004_ref_119" ref-type="bibr">119</xref>]. Individuals with opioid use disorders are already vulnerable to poor health and the emergence of SARS-CoV-2 has further put these individuals in a compromised situation [<xref rid="j_nipt-2023-0004_ref_120" ref-type="bibr">120</xref>].</p><p>Although there have not been specific studies conducted on the molecular effects of opioid abuse on SARS-CoV-2 infection, many published articles have established a correlation between the effect of opioid abuse on individuals&#8217; health and the risk that may be presented when people with opioid use disorders (OUDs) are infected with the virus [<xref rid="j_nipt-2023-0004_ref_118" ref-type="bibr">118</xref>, <xref rid="j_nipt-2023-0004_ref_121" ref-type="bibr">121</xref>, <xref rid="j_nipt-2023-0004_ref_122" ref-type="bibr">122</xref>]. A report published by Willner et&#160;al., suggested that COVID-19 and opioid exposure may have similar disease outcomes including respiratory depression and hypoxia, and that the combination of these two could lead to an aggravated complication in both neuro-immunity and respiratory depression [<xref rid="j_nipt-2023-0004_ref_123" ref-type="bibr">123</xref>, <xref rid="j_nipt-2023-0004_ref_124" ref-type="bibr">124</xref>]. Opioids stimulate increased levels of pro-inflammatory and neurotoxic cytokines such as IL-6, IL-1&#946;, and TNF&#945; as well as anti-inflammatory and neuroprotective cytokines like IL-10, TGF-&#946;, and BDNF when they bind to opioid receptors in the central nervous system [<xref rid="j_nipt-2023-0004_ref_125" ref-type="bibr">125</xref>, <xref rid="j_nipt-2023-0004_ref_126" ref-type="bibr">126</xref>]. Similarly, stimulation of inflammatory damages has been observed in some COVID-19 patients diagnosed with neurological symptoms, including encephalitis that may be due to neuroimmunological responses [<xref rid="j_nipt-2023-0004_ref_123" ref-type="bibr">123</xref>, <xref rid="j_nipt-2023-0004_ref_127" ref-type="bibr">127</xref>]. Due to these similar inflammatory damages to the central nervous system, a combination of opioid abuse and COVID-19 may lead to detrimental health risks [<xref rid="j_nipt-2023-0004_ref_127" ref-type="bibr">127</xref>].</p><p>Another study suggests that opioid users are at an increase from COVID-19 due to the suppression of immune functions by opioids [<xref rid="j_nipt-2023-0004_ref_119" ref-type="bibr">119</xref>]. Opioids inhibit leukocyte recruitment, cytokine secretion, and have a destructive effect on innate and adaptive cells. A study by Zhao et&#160;al. in SARS-related infected mice showed that inefficient T-cell activation may potentiate lung injury [<xref rid="j_nipt-2023-0004_ref_128" ref-type="bibr">128</xref>]. This relationship between opioid users and SARS-CoV-2 may worsen immunological disease outcomes in persons with OUD.</p></sec><sec id="j_nipt-2023-0004_s_005_s_002"><title>Systemic/organ effects</title><p>Opioids can lead to both respiratory depression and kidney damage. COVID-19 can also cause severe acute respiratory infections in many patients [<xref rid="j_nipt-2023-0004_ref_129" ref-type="bibr">129</xref>]. There is also a high prevalence of kidney impairment in hospitalized COVID-19 patients [<xref rid="j_nipt-2023-0004_ref_130" ref-type="bibr">130</xref>]. Taken together, there is an increased risk for poor prognosis and death in patients with COVID-19 who abuse opioids [<xref rid="j_nipt-2023-0004_ref_129" ref-type="bibr">129</xref>, <xref rid="j_nipt-2023-0004_ref_130" ref-type="bibr">130</xref>]. Opioid-related respiratory depression may result in hypoxemia [<xref rid="j_nipt-2023-0004_ref_119" ref-type="bibr">119</xref>]. As early as 6&#8201;months after starting opioid use, the risks of respiratory depression can range from 1.9 to 83.4&#8239;% [<xref rid="j_nipt-2023-0004_ref_131" ref-type="bibr">131</xref>]. COVID-19 additionally can cause hypoxemia secondary to viral pneumonia, and one large study showed the frequency of hypoxemia in hospitalized patients was 20.4&#8239;% [<xref rid="j_nipt-2023-0004_ref_024" ref-type="bibr">24</xref>]. This demonstrates the potential for increased risks of opioid-related respiratory depression with concomitant hypoxemia from viral pneumonia. Opioid use in patients who become infected with COVID-19 may result in an increased risk of adverse respiratory outcomes [<xref rid="j_nipt-2023-0004_ref_119" ref-type="bibr">119</xref>]. The usage of opioids leads to multiple complex interactions throughout various body systems, particularly the endocrine and nervous systems, altering both the sympathetic and parasympathetic autonomic nervous system, so the effects of opioids on renal function may increase the risk of hospital death [<xref rid="j_nipt-2023-0004_ref_130" ref-type="bibr">130</xref>]. Heroin use is linked with a higher risk of CKD progression [<xref rid="j_nipt-2023-0004_ref_132" ref-type="bibr">132</xref>]. This is important for patients hospitalized with COVID-19 and who are also receiving nephrotoxic agents in the hospital, because it may worsen their prognosis. Therefore, it is important to recognize patients with opioid use early in order to improve their chances of recovery [<xref rid="j_nipt-2023-0004_ref_133" ref-type="bibr">133</xref>]. In addition to chronic kidney disease (CKD) causing poorer prognoses, acute kidney injury (AKI) is also a major concern for increasing the risk for SARS-CoV-2 complications in patients with opioid use disorders. AKI with opioid use develops through a mechanism of multi-organ failure from respiratory depression, hypoxia, and volume depletion with or without rhabdomyolysis [<xref rid="j_nipt-2023-0004_ref_134" ref-type="bibr">134</xref>]. Also, an overdose of opioids can result in AKI as a consequence of different mechanisms such as dehydration, hypotension, rhabdomyolysis, and urinary retention [<xref rid="j_nipt-2023-0004_ref_135" ref-type="bibr">135</xref>]. The significance of AKI is described in a study that showed the relationship between AKI and COVID-19 and found that AKI occurs early and is accompanied by respiratory failure, which is associated with poor COVID outcomes including ventilation, renal replacement therapy, and death [<xref rid="j_nipt-2023-0004_ref_089" ref-type="bibr">89</xref>]. Therefore, kidney damage caused by opioid use can further increase the user&#8217;s risk for AKI with COVID-19 infection and lead to poor recovery outcomes for these patients. This supports that respiratory depression and kidney damage caused by opioids significantly increase the risks of a poor prognosis and death with SARS-CoV-2 infection.</p><p>The published data suggest a negative correlation between OUD and COVID-19, although there is relatively little data to date there is the need for distinct evidence to support the potential cause for worsen disease outcome in persons with OUD as these populations are vulnerable and have a high risk of death.</p></sec></sec><sec id="j_nipt-2023-0004_s_006"><title>Effect of methamphetamine use on SARS-CoV-2</title><p>Methamphetamine is a common drug of abuse used by people regardless of age. Methamphetamine use is usually preceded by a previous drug abuse history with opioids, alcohol, cocaine, or heroin. A study conducted from December 2019 to November 2020 during the early stages of the COVID-19 pandemic found that methamphetamine use increased 37&#8239;% from the previous year [<xref rid="j_nipt-2023-0004_ref_136" ref-type="bibr">136</xref>]. People living with substance use disorders have been shown to be significantly more vulnerable to complications arising from COVID-19 infection due to respiratory and cardiovascular from substance abuse especially due to methamphetamine [<xref rid="j_nipt-2023-0004_ref_137" ref-type="bibr">137</xref>]. Methamphetamine, which has several forms such as powder or an oily substance, is most commonly smoked and in chronic users has been shown to cause lung complications such as pulmonary toxicity [<xref rid="j_nipt-2023-0004_ref_137" ref-type="bibr">137</xref>] and neurotoxicity [<xref rid="j_nipt-2023-0004_ref_138" ref-type="bibr">138</xref>].</p><sec id="j_nipt-2023-0004_s_006_s_001"><title>Molecular effects</title><p>Methamphetamines euphoric effects are caused by monoamines released during use that act on the dopaminergic, noradrenergic, and serotonergic pathways in the neurological system. Dopamine then can target central pathways such as the nigrostriatal pathway and the mesocortical and mesolimbic circuit [<xref rid="j_nipt-2023-0004_ref_139" ref-type="bibr">139</xref>]. Distribution of these monoamines is not only limited to the neurological system but others which enhances methamphetamines systemic effect.</p><p>Methamphetamine can impact the immune system in a few ways. Altering the efficiency of B cells and disrupting communication between the innate and adaptive cells by cytokines may delay response to pathogens such as COVID-19. Methamphetamine can reduce the numbers of circulating immune cells such as dendritic cells, monocytes, natural killer cells and macrophages, predisposing these users to a higher risk of infection for all viruses, including SARS-CoV-2 [<xref rid="j_nipt-2023-0004_ref_140" ref-type="bibr">140</xref>].</p><p>Methamphetamine causes damage to the lungs by increasing oxidative stress [<xref rid="j_nipt-2023-0004_ref_138" ref-type="bibr">138</xref>]. In conditions of oxidative stress, dopamine (DA) can oxidize to form superoxide and hydrogen peroxide, which can then form the hydroxyl radicals [<xref rid="j_nipt-2023-0004_ref_138" ref-type="bibr">138</xref>]. These radicals produced are implicated in methamphetamine induced pulmonary toxicity. DA oxidation forms DA quinones which participates in addition reactions with sulfhydryl groups on free cysteine. This reaction can cause a cascade of reactions including decreasing antioxidant concentrations and can result in decreased lung function over time [<xref rid="j_nipt-2023-0004_ref_138" ref-type="bibr">138</xref>]. Lung function is critically important to maintain in patients with COVID-19 due to the increased risk of mortality with impaired lung function this becomes especially important in those with a previous history of lung damage such as those with chronic methamphetamine use. COVID-19 also causes respiratory stress through similar mechanisms from methamphetamine. Monocytes and macrophages play a critical role in the inflammatory reactions with severe COVID-19 infection [<xref rid="j_nipt-2023-0004_ref_141" ref-type="bibr">141</xref>]. These immune cells release large amounts of pro-inflammatory cytokines such as IL-6 and IL-8 [<xref rid="j_nipt-2023-0004_ref_141" ref-type="bibr">141</xref>]. Increases in the same pro-inflammatory cytokines released in COVID-19 and methamphetamine use could predispose methamphetamine users to an increased risk of developing respiratory distress from COVID-19.</p><p>Methamphetamine causes an increase in inflammatory markers such as LC3 [<xref rid="j_nipt-2023-0004_ref_137" ref-type="bibr">137</xref>]. Further, it causes infiltration of inflammatory cells into the lungs causing thickening of alveolar sputum, compacting lung parenchyma, and reduction in the amount of alveolar sacs [<xref rid="j_nipt-2023-0004_ref_137" ref-type="bibr">137</xref>]. An increase in autophagic regulator protein LC3 causes cellular apoptosis by decreasing anti-apoptosis mediated BCL2. Cellular apoptosis in alveolar epithelial cells has been shown to cause pulmonary toxicity in chronic methamphetamine users [<xref rid="j_nipt-2023-0004_ref_137" ref-type="bibr">137</xref>]. SARS-CoV-2 damages the alveolar-capillary barrier by loss of surfactant protein expression causing injury to alveolar epithelial cells, endothelial cells, respiratory epithelial basal cells, and damages to tissue repair processes [<xref rid="j_nipt-2023-0004_ref_142" ref-type="bibr">142</xref>].</p><p>Neurodegenerative changes in methamphetamine users are also commonly seen in those with chronic use. Changes such as a loss of dopamine transporters, serotonin transporters, and a loss of dopamine levels have been found in brains of methamphetamine users [<xref rid="j_nipt-2023-0004_ref_143" ref-type="bibr">143</xref>]. Brain scans of this population also show a change in the brain&#8217;s anatomy regarding amounts of white and gray matter [<xref rid="j_nipt-2023-0004_ref_143" ref-type="bibr">143</xref>]. The SARS-CoV-2 virus has also been found to impact neurotransmitters such as dopamine and serotonin. SARS&#8208;CoV2&#8208;induced downregulation of ACE2 expression is accompanied by changes in both reduced dopamine and serotonin production, which is exacerbated by chronic use of methamphetamine. Loss of dopamine and serotonin in both disease states could increase the risk of neurodegenerative changes seen in patients with COVID-19 [<xref rid="j_nipt-2023-0004_ref_014" ref-type="bibr">14</xref>].</p><p>Neurotoxicity induced by methamphetamine is caused by a decrease in DA, DA transporter, serotonin vesicular monoamine transporter type 2 (VMAT2), and tyrosine hydroxylase [<xref rid="j_nipt-2023-0004_ref_143" ref-type="bibr">143</xref>]. Due to a decrease in VMAT2, an increased risk of neurological conditions such as Parkinson&#8217;s are found to be more common in methamphetamine users versus non-methamphetamine users [<xref rid="j_nipt-2023-0004_ref_138" ref-type="bibr">138</xref>]. The use of alcohol in methamphetamine users may further exacerbate neurotoxicity associated with methamphetamine. One study found that dopamine levels decreased by 90&#8239;% when alcohol use was recently prior to the use of methamphetamine [<xref rid="j_nipt-2023-0004_ref_144" ref-type="bibr">144</xref>]. Alcohol can induce COX2 in the brain and COX2 has been linked to cause neurotoxicity with methamphetamine use [<xref rid="j_nipt-2023-0004_ref_144" ref-type="bibr">144</xref>].</p></sec><sec id="j_nipt-2023-0004_s_006_s_002"><title>Systemic/organ effects</title><p>Methamphetamine is an amphetamine analog most commonly smoked using various non-sterile methods with some exposing users to dangerous unknown drugs and bacteria. Chronic use has been associated with immunosuppression, causing a lower immune response to fight off infections such as COVID-19 [<xref rid="j_nipt-2023-0004_ref_145" ref-type="bibr">145</xref>]. Chronic use has been shown to particularly affect immune dysregulation in the lungs which can be a major concern in those with COVID-19 [<xref rid="j_nipt-2023-0004_ref_146" ref-type="bibr">146</xref>]. Methamphetamine users are at increased risk due to the likelihood that they already suffer from existing diseases, weakened immunity, poor decision making, and impaired judgment, all of which can increase their susceptibility to infection [<xref rid="j_nipt-2023-0004_ref_140" ref-type="bibr">140</xref>]. Methamphetamine users have a weakened immune system which makes them susceptible to opportunistic infections [<xref rid="j_nipt-2023-0004_ref_140" ref-type="bibr">140</xref>].</p><p>The pathogenesis of methamphetamine induced lung injury is not well understood but chronic use has been linked to lung damage [<xref rid="j_nipt-2023-0004_ref_147" ref-type="bibr">147</xref>]. Inhalation of methamphetamine may be associated with an increase in free radical formation [<xref rid="j_nipt-2023-0004_ref_147" ref-type="bibr">147</xref>]. Free radical formation in the lungs as previously discussed can cause irreversible damage from chronic methamphetamine use. Damage from methamphetamine has been known to cause lung damage leading to pulmonary edema, pneumonia, and pulmonary hypertension [<xref rid="j_nipt-2023-0004_ref_147" ref-type="bibr">147</xref>]. With a majority of methamphetamine damage affecting the lungs it is critical to associate methamphetamine use with worsening outcomes in active COVID patients.</p><p>Cognitive impairments from methamphetamine use results in neurological deficits such as memory loss and changes in decision making and information processing [<xref rid="j_nipt-2023-0004_ref_143" ref-type="bibr">143</xref>]. Methamphetamine use is also associated with an increased risk of seizures, coma, agitation, anxiety, depression, paranoia, and psychosis [<xref rid="j_nipt-2023-0004_ref_143" ref-type="bibr">143</xref>]. COVID is also associated with neurological symptoms during active infection and long after eradication of the virus from the body in some patients. The term &#8220;covid fog/brain&#8221; has been widely used since the beginnings of the pandemic to describe consequences of the virus for descriptions of cognitive impairment [<xref rid="j_nipt-2023-0004_ref_148" ref-type="bibr">148</xref>]. People described this as a slowing down in their speed of information processing and decreased short-term memory. Mood and sleep disorders are also common of &#8220;long covid&#8221; with symptoms lasting over 4 weeks after illness [<xref rid="j_nipt-2023-0004_ref_148" ref-type="bibr">148</xref>]. With COVID-19, disease symptoms can continue for extensive periods after the infection&#8217;s resolution. As many as 87&#8239;% of people reported having at least one persistent symptom after 4 weeks of infection resolution [<xref rid="j_nipt-2023-0004_ref_148" ref-type="bibr">148</xref>].</p><p>With chronic use of methamphetamine, brain damage predisposes these patients to both neurologic and pulmonary COVID complications. Further research is required to see if neurological deficits related to methamphetamine use could put people at risk of developing long term complications of COVID such as the cognitive impairments mentioned above. Due to methamphetamine and COVID targeting similar organs, the brain and lungs, a correlation could be drawn that each will negatively affect the other. Brain and lung damage in methamphetamine users could impact COVID infection and its consequences. Just as in people with chronic lung conditions such as asthma or chronic obstructive pulmonary disease, people who use methamphetamine may have negative impacts on disease progression with COVID-19 due to previous damage from methamphetamine.</p></sec></sec><sec id="j_nipt-2023-0004_s_007"><title>Effect of cocaine use on SARS-CoV-2</title><p>In 2021, a national survey was used to conduct the usage of cocaine among people 12 years or older in the United States. In the last 12 months, there were around 4.8 million people that reported the use of cocaine [<xref rid="j_nipt-2023-0004_ref_149" ref-type="bibr">149</xref>]. In the United States, cocaine is a schedule 2 drug, with a high potential for abuse. It is one of the most powerful addictive stimulants used globally. During the COVID-19 pandemic, there has been an increased surge of people experiencing depression or anxiety, leading to cocaine use [<xref rid="j_nipt-2023-0004_ref_136" ref-type="bibr">136</xref>].</p><sec id="j_nipt-2023-0004_s_007_s_001"><title>Molecular effects</title><p>Cocaine is an addictive substance, that with excess consumption causes major complications. The exposure side effects of cocaine use are seen in many areas in the body, including the brain, cardiovascular, lungs, and immune system [<xref rid="j_nipt-2023-0004_ref_149" ref-type="bibr">149</xref>]. The abuse of cocaine activates a specific innate immune response that leads to major cellular toxicities in the brain, heart, and other respective organs. The activation of these components alters homeostasis in the CNS system and increases the production of the of pro-inflammatory cytokine IL-6 and then decreases the expression of the anti-inflammatory cytokine IL-10 [<xref rid="j_nipt-2023-0004_ref_150" ref-type="bibr">150</xref>]. Several studies have shown that cocaine can promote the oxidative stress in the organs mentioned above, hence increasing the reactive oxygen species production [<xref rid="j_nipt-2023-0004_ref_150" ref-type="bibr">150</xref>]. It is important to understand the role of these inflammatory cytokines due to the concern for patients with cocaine abuse that also have a COVID-19 infection. Cocaine affects the immune system by stimulating the hypothalamic&#8211;pituitary&#8211;adrenal axis which affects the antibody formation, lymphocyte proliferation, macrophage and NK activation; causing high incidence of viral infection [<xref rid="j_nipt-2023-0004_ref_076" ref-type="bibr">76</xref>]. This is a concern in SARS-CoV-2 due to a clinical study showing that there was a significant rise in the levels of different cytokines. In COVID-19, the cytokine IL-6 showed high levels of interest due to secreting the protein in the lung epithelial cell [<xref rid="j_nipt-2023-0004_ref_151" ref-type="bibr">151</xref>]. Due to similar synergistic effect with COVID-19, there is a major concern with the increased risk of infections, pneumonia, pulmonary embolism and asthma exacerbation [<xref rid="j_nipt-2023-0004_ref_152" ref-type="bibr">152</xref>].</p><p>As mentioned, COVID-19 and the use of cocaine concomitantly leads to an increase of inflammatory markers, leading to a higher risk of complication for the patient. The next section will bring into account the need to discuss the organs that are affected by the combination of both stimulant and virus.</p></sec><sec id="j_nipt-2023-0004_s_007_s_002"><title>Systemic/organ effects</title><p>Cocaine can be administered in many different ways, including intranasally, inhalation or intravenously. Patients with a cocaine use disorder can experience many side effects by the usage of cocaine only. When combined with the COVID-19 infection, these side effects can lead to major complications. As mentioned, patients with COVID-19 who have a cocaine use disorder will have a greater chance of having COVID-19 complications, but this does not correlate with decreased life expectancy [<xref rid="j_nipt-2023-0004_ref_136" ref-type="bibr">136</xref>]. A study showed that patients with COVID-19 and cocaine use disorder had worse outcomes in death and hospitalization than patients without cocaine use disorder [<xref rid="j_nipt-2023-0004_ref_153" ref-type="bibr">153</xref>]. Cocaine use is associated with effects on organs throughout the body, including the cardiovascular, CNS, and respiratory systems.</p><p>Cocaine stimulates the sympathetic nervous system leading to the inhibition of catecholamines re-uptake, affecting the cardiovascular system [<xref rid="j_nipt-2023-0004_ref_154" ref-type="bibr">154</xref>]. Additionally, cocaine increases myocardial oxygen demand by increasing the patient&#8217;s heart rate and blood pressure. A retrospective cohort study showed that patients with cocaine use disorder diagnosed with COVID-19 had a further risk of new diagnosis of endocarditis [<xref rid="j_nipt-2023-0004_ref_155" ref-type="bibr">155</xref>]. The synergistic effect of COVID-19 and the consumption of cocaine has a prothrombic and hypercoagulable effect increasing the risk of myocardial infraction [<xref rid="j_nipt-2023-0004_ref_156" ref-type="bibr">156</xref>].</p><p>Cocaine can also affect the respiratory system therefore exacerbating the synergistic effect of COVID-19 in the lungs. After developing cocaine toxicity, some pulmonary complications are seen, with patients experiencing shortness of breath, wheezing, and chest pain [<xref rid="j_nipt-2023-0004_ref_157" ref-type="bibr">157</xref>]. In patients with active cases of COVID-19, these symptoms can be exacerbated, increasing the risk of pulmonary complications in these patients [<xref rid="j_nipt-2023-0004_ref_158" ref-type="bibr">158</xref>].</p><p>People with a cocaine use disorder are considered more susceptible to the infection of SARS-CoV-2 which has brought into concern the neurological symptom as well. Cocaine produces its effects in the brain by stimulating the mesolimbic dopamine system causing similar symptoms in COVID-19. SARS-CoV-2 and cocaine have a synergistic effect on the blood brain barrier (BBB), increasing the permeability to toxins, therefore causing an increased risk in the central nervous system. The disruption of the BBB permeability exacerbates the symptoms encountered in both cocaine use and COVID-19 [<xref rid="j_nipt-2023-0004_ref_076" ref-type="bibr">76</xref>]. The damage of the endothelial cells in the brain is due to the entrance of both cocaine and COVID-19 through the angiotensin-converting enzyme 2 receptors. The activation of these pro-inflammatory markers in the brain will cause patients to experience neurotoxic effects [<xref rid="j_nipt-2023-0004_ref_159" ref-type="bibr">159</xref>]. This causes more concern and monitoring for patients with cocaine use disorder and COVID-19 [<xref rid="j_nipt-2023-0004_ref_159" ref-type="bibr">159</xref>].</p></sec></sec><sec id="j_nipt-2023-0004_s_008"><title>Cannabinoids and COVID-19</title><p>The purchase of CBD, a component of the cannabinoid family, has increased in popularity due to availability without a prescription. CBD is being used for many different reasons, including stress, anxiety, sleep and pain. Increased ease of access has led to increased consumption. There is, however, concern for the side effects of CBD due to limited data in their safety and efficacy [<xref rid="j_nipt-2023-0004_ref_160" ref-type="bibr">160</xref>].</p><p>The properties of cannabinoids depend on their interaction with the endocannabinoid system including G-proteins coupled receptors and transient receptor potential channels [<xref rid="j_nipt-2023-0004_ref_161" ref-type="bibr">161</xref>]. CBD1 and CBD2 have a role in immunity by suppressing T-cell activation, inhibiting IL-17 secretion and regulation of intestinal neutrophils [<xref rid="j_nipt-2023-0004_ref_161" ref-type="bibr">161</xref>]. CBD can reduce proinflammatory cytokines IL-2, IL-6, IL-1&#945; and &#946;, interferon gamma, and inducible protein-10 that have been associated with SARS-CoV-2 [<xref rid="j_nipt-2023-0004_ref_160" ref-type="bibr">160</xref>]. Cytokines previously mentioned play a central role in the inflammatory response to COVID-19.</p><p>Pre-clinical studies show that some cannabinoids may have an impact on the inflammatory response in mouse models of lung or inflammatory diseases [<xref rid="j_nipt-2023-0004_ref_161" ref-type="bibr">161</xref>]. Inhibition of key pro-inflammatory cytokines TNF&#945; and IL-6 were found in this study along with decreased levels of cytokines IL-5, IL-4 and IL-13 by CBD via the CB1 receptor [<xref rid="j_nipt-2023-0004_ref_161" ref-type="bibr">161</xref>]. This led to a reduction in airway inflammation, a key problem with COVID-19 infections. Cannabinoids may hold the potential for avoiding cytokine release which is responsible for most of the inflammatory mediated effects of COVID-19.</p><p>One study assessed antiviral activity of CBD and &#916;9-THC against SARS-CoV-2. The study showed blocking of viral translation of SARS-CoV-2 and reducing pro-inflammatory cytokines levels in the lungs by acting as agonists of the CB-2 receptor [<xref rid="j_nipt-2023-0004_ref_162" ref-type="bibr">162</xref>]. &#916;9-THC acts as a partial agonist of CB1R and CB2R and reportedly induces immunological and anti-inflammatory effects via activation of CB2R [<xref rid="j_nipt-2023-0004_ref_162" ref-type="bibr">162</xref>]. Cannabinoids are supported by evidence to be an addition to current COVID-19 therapies [<xref rid="j_nipt-2023-0004_ref_008" ref-type="bibr">8</xref>].</p><p>Other studies have assessed if CBD could help with the rise in mental health conditions from the COVID-19 pandemic. Due to the pandemic an unprecedented outcome was established between the pandemic and neurological complications such as anxiety and depression. An estimate of 45&#8239;% of adults in the US reported that their mental health was affected due to the COVID-19 pandemic [<xref rid="j_nipt-2023-0004_ref_015" ref-type="bibr">15</xref>]. Due to lack of evidence or well-designed clinical trials, data does not suggest a benefit of CBD on mental health conditions such as anxiety or depression [<xref rid="j_nipt-2023-0004_ref_015" ref-type="bibr">15</xref>].</p><p>In a study on the interaction between cannabinoids and SARS-CoV-2 spike protein, an interaction was found that two cannabinoids, cannabidolic acid and cannabigerolic acid, may block infection of human cells by SARS-CoV-2 expressing the spike protein [<xref rid="j_nipt-2023-0004_ref_163" ref-type="bibr">163</xref>]. Blocking viral attachment to human cells helps decrease viral replication and viral infection.</p><p>The anti-inflammatory properties of CBD may be beneficial for preventing worsening of disease from inflammation due to COVID-19, but caution is needed regarding the risk of abuse with cannabinoids and guideline recommended alternative therapies with no risk of abuse or addiction unlike cannabinoids.</p></sec><sec id="j_nipt-2023-0004_s_009"><title>Conclusions</title><p>Dependence on drugs of abuse is associated to increased morbidity and mortality [<xref rid="j_nipt-2023-0004_ref_017" ref-type="bibr">17</xref>, <xref rid="j_nipt-2023-0004_ref_019" ref-type="bibr">19</xref>, <xref rid="j_nipt-2023-0004_ref_022" ref-type="bibr">22</xref>]. These substances when abused can affect the respiratory, cardiovascular, and psychological systems. SARS-CoV-2, the causative agent of COVID-19 also affects these organs and systems, particularly the respiratory system [<xref rid="j_nipt-2023-0004_ref_017" ref-type="bibr">17</xref>, <xref rid="j_nipt-2023-0004_ref_019" ref-type="bibr">19</xref>, <xref rid="j_nipt-2023-0004_ref_022" ref-type="bibr">22</xref>]. The possibility and potential for these two epidemics and pandemic to cause worsened disease outcome in persons with SUD needs to be understood. We have reviewed the molecular and organic/systemic impact SARS-CoV-2 has on individuals with substance use disorders.</p><p>Chronic alcohol consumption leads to increased SARS-CoV-2 infectivity and viral susceptibility. Alcohol consumption increases ACE2 expression, the entry point of the pathogen while altering proinflammatory cytokines [<xref rid="j_nipt-2023-0004_ref_034" ref-type="bibr">34</xref>, <xref rid="j_nipt-2023-0004_ref_038" ref-type="bibr">38</xref>]. Heavy alcohol use is also associated with respiratory system decline by altering macrophages and lymphocyte recruitment which is essential in clearing SARS-CoV-2 pathogens [<xref rid="j_nipt-2023-0004_ref_030" ref-type="bibr">30</xref>]. This results in respiratory system decline for persons with AUD.</p><p>Although some studies suggest that tobacco (nicotine) may protect the lungs against SARS-CoV-2 by restoring the NCS and anti-inflammatory pathway, more recent studies suggest otherwise [<xref rid="j_nipt-2023-0004_ref_066" ref-type="bibr">66</xref>]. Nicotine has been found to upregulate ACE2 expression in the lower respiratory tract, the entry point for SARS-CoV-2 and increase viral infectivity by altering the immune functions [<xref rid="j_nipt-2023-0004_ref_056" ref-type="bibr">56</xref>].</p><p>Similarly, studies on marijuana (cannabis) use suggest it may have some therapeutic effect in protecting the lungs by acting as an immunomodulatory agent in suppressing cytokine storm triggered by SARS-CoV-2 [<xref rid="j_nipt-2023-0004_ref_083" ref-type="bibr">83</xref>&#8211;<xref rid="j_nipt-2023-0004_ref_085" ref-type="bibr">85</xref>]. Although this is confirmed by the decreased odd ratio of contracting the pathogen than in people with opioid, tobacco and alcohol use disorders, the risk is much greater than people with no history of substance abuse [<xref rid="j_nipt-2023-0004_ref_107" ref-type="bibr">107</xref>]. Marijuana may have some therapeutic effect against SARA-CoV-2, but its side effect should not be disregarded in terms of drug-drug interaction against other COVID-19 medications [<xref rid="j_nipt-2023-0004_ref_090" ref-type="bibr">90</xref>].</p><p>The vulnerability of people with opioid use disorders put them in a comprised health situations when infected with SARS-CoV-2 [<xref rid="j_nipt-2023-0004_ref_116" ref-type="bibr">116</xref>]. Although there has not been any research conducted at the molecular or organic/systemic level to observe the direct effect, there is a suggestion that the combination of the individual health repercussion in OUD and SARS-CoV-2 infection could lead to aggravated complications in these individuals. Considering the high rates of respiratory depression and kidney impairment in individuals with opioid use disorders and COVID-19 patients, a patient with OUD affected with the disease could be detrimental [<xref rid="j_nipt-2023-0004_ref_129" ref-type="bibr">129</xref>].</p><p>Methamphetamine and cocaine have similar detrimental effects on outcomes in patients with COVID-19. Effects on immune suppression and pulmonary toxicity seen in methamphetamine and cocaine users negatively impact patients with poor health outcomes with infection of SARS-CoV-2. Immune suppression predisposes this population to an increased risk of infections and a lesser ability to fight off the infection while pulmonary alterations can lead to worsening pulmonary complications as seen with COVID-19.</p><p>Finally, cannabinoids have been shown to have anti-inflammatory properties as well as inhibiting viral attachment to human cells, which helps decrease the likelihood of infections with SARS-CoV-2. While certain cannabinoids show a benefit with inflammation due to viral infections, large concerns include lack of data on safety and efficacy of cannabinoids especially those taken without the Food and Drug Administration approval or oversight.</p><p>People with substance use disorders have comprised health conditions which makes them more susceptible to pathogen infectivity. Considering this factor, there could be some synergistic effect that poses as a potential cause for worsened disease outcome in these population. However, more research must be conducted to indicate a direct association of the effect SARS-CoV-2 has on persons with substance use disorders.</p></sec></body><back><fn-group><fn fn-type="other" id="j_nipt-2023-0004_fn_005"><p><bold>Ethical approval:</bold> Not applicable.</p></fn><fn fn-type="other" id="j_nipt-2023-0004_fn_004"><p><bold>Informed consent:</bold> Not applicable.</p></fn><fn fn-type="con" id="j_nipt-2023-0004_fn_002"><p><bold>Author contributions:</bold> All authors have accepted responsibility for the entire content of this manuscript and approved its submission.</p></fn><fn fn-type="COI-statement" id="j_nipt-2023-0004_fn_003"><p><bold>Competing interests:</bold> Authors state no conflict of interest.</p></fn><fn fn-type="financial-disclosure" id="j_nipt-2023-0004_fn_001"><p><bold>Research funding:</bold> R01DA047178 to TJC.</p></fn></fn-group><ref-list id="j_nipt-2023-0004_reflist_001"><title>References</title><ref id="j_nipt-2023-0004_ref_001"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machhi</surname><given-names>J</given-names></name><name name-style="western"><surname>Herskovitz</surname><given-names>J</given-names></name><name name-style="western"><surname>Senan</surname><given-names>AM</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>D</given-names></name><name name-style="western"><surname>Nath</surname><given-names>B</given-names></name><name name-style="western"><surname>Oleynikov</surname><given-names>MD</given-names></name><etal/></person-group><article-title>The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections</article-title><source>J Neuroimmune Pharmacol</source><year>2020</year><volume>15</volume><fpage>359</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/s11481-020-09944-5</pub-id><pub-id pub-id-type="pmid">32696264</pub-id><pub-id pub-id-type="pmcid">PMC7373339</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_002"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Coronavirus disease 2019 (COVID-19): situation report, 51</source><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name><year>2020</year></element-citation></ref><ref id="j_nipt-2023-0004_ref_003"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>JB</given-names></name><name name-style="western"><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>Cytokine release syndrome in severe COVID-19</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>473</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1126/science.abb8925</pub-id><pub-id pub-id-type="pmid">32303591</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_004"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Niu</surname><given-names>S</given-names></name><name name-style="western"><surname>Song</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Structural and functional basis of SARS-CoV-2 entry by using human ACE2</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>894</fpage><lpage>904.e9</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.045</pub-id><pub-id pub-id-type="pmid">32275855</pub-id><pub-id pub-id-type="pmcid">PMC7144619</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_005"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Weiskopf</surname><given-names>D</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>SI</given-names></name><name name-style="western"><surname>Mateus</surname><given-names>J</given-names></name><name name-style="western"><surname>Dan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Moderbacher</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>1489</fpage><lpage>501.e15</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.015</pub-id><pub-id pub-id-type="pmid">32473127</pub-id><pub-id pub-id-type="pmcid">PMC7237901</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_006"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>MD</given-names></name></person-group><article-title>Macrophages: a trojan horse in COVID-19?</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><fpage>351</fpage><pub-id pub-id-type="doi">10.1038/s41577-020-0317-2</pub-id><pub-id pub-id-type="pmcid">PMC7186930</pub-id><pub-id pub-id-type="pmid">32303696</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_007"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Fujiogi</surname><given-names>M</given-names></name><name name-style="western"><surname>Koutsogiannaki</surname><given-names>S</given-names></name></person-group><article-title>COVID-19 pathophysiology: a review</article-title><source>Clin Immunol</source><year>2020</year><volume>215</volume><fpage>108427</fpage><pub-id pub-id-type="doi">10.1016/j.clim.2020.108427</pub-id><pub-id pub-id-type="pmid">32325252</pub-id><pub-id pub-id-type="pmcid">PMC7169933</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_008"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Feng</surname><given-names>F</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19</article-title><source>Front Mol Biosci</source><year>2020</year><volume>7</volume><fpage>157</fpage><pub-id pub-id-type="doi">10.3389/fmolb.2020.00157</pub-id><pub-id pub-id-type="pmid">32719810</pub-id><pub-id pub-id-type="pmcid">PMC7350507</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_009"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>DKW</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>SMS</given-names></name><name name-style="western"><surname>Hui</surname><given-names>KPY</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia</article-title><source>Clin Chem</source><year>2020</year><volume>66</volume><fpage>549</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1093/clinchem/hvaa029</pub-id><pub-id pub-id-type="pmid">32031583</pub-id><pub-id pub-id-type="pmcid">PMC7108203</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_010"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lescure</surname><given-names>FX</given-names></name><name name-style="western"><surname>Bouadma</surname><given-names>L</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D</given-names></name><name name-style="western"><surname>Parisey</surname><given-names>M</given-names></name><name name-style="western"><surname>Wicky</surname><given-names>PH</given-names></name><name name-style="western"><surname>Behillil</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical and virological data of the first cases of COVID-19 in Europe: a case series</article-title><source>Lancet Infect Dis</source><year>2020</year><volume>20</volume><fpage>697</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(20)30200-0</pub-id><pub-id pub-id-type="pmid">32224310</pub-id><pub-id pub-id-type="pmcid">PMC7156120</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_011"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#8211;infected pneumonia in Wuhan, China</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1061</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id><pub-id pub-id-type="pmid">32031570</pub-id><pub-id pub-id-type="pmcid">PMC7042881</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_012"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ornell</surname><given-names>F</given-names></name><name name-style="western"><surname>Moura</surname><given-names>HF</given-names></name><name name-style="western"><surname>Scherer</surname><given-names>JN</given-names></name><name name-style="western"><surname>Pechansky</surname><given-names>F</given-names></name><name name-style="western"><surname>Kessler</surname><given-names>FHP</given-names></name><name name-style="western"><surname>von Diemen</surname><given-names>L</given-names></name></person-group><article-title>The COVID-19 pandemic and its impact on substance use: implications for prevention and treatment</article-title><source>Psychiatr Res</source><year>2020</year><volume>289</volume><fpage>113096</fpage><pub-id pub-id-type="doi">10.1016/j.psychres.2020.113096</pub-id><pub-id pub-id-type="pmcid">PMC7219362</pub-id><pub-id pub-id-type="pmid">32405115</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_013"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>J</given-names></name><name name-style="western"><surname>Mason</surname><given-names>R</given-names></name><name name-style="western"><surname>Siriwardena</surname><given-names>AN</given-names></name><name name-style="western"><surname>Hogue</surname><given-names>T</given-names></name><name name-style="western"><surname>Whitley</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Alcohol and other substance use during the COVID-19 pandemic: a systematic review</article-title><source>Drug Alcohol Depend</source><year>2021</year><volume>229</volume><fpage>109150</fpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.109150</pub-id><pub-id pub-id-type="pmid">34749198</pub-id><pub-id pub-id-type="pmcid">PMC8559994</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_014"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubin</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Wessely</surname><given-names>S</given-names></name></person-group><article-title>The psychological effects of quarantining a city</article-title><source>BMJ</source><year>2020</year><volume>368</volume><fpage>m313</fpage><pub-id pub-id-type="doi">10.1136/bmj.m313</pub-id><pub-id pub-id-type="pmid">31992552</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_015"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalsa</surname><given-names>JH</given-names></name><name name-style="western"><surname>Bunt</surname><given-names>G</given-names></name><name name-style="western"><surname>Maggirwar</surname><given-names>SB</given-names></name><name name-style="western"><surname>Kottilil</surname><given-names>S</given-names></name></person-group><article-title>COVID-19 and cannabidiol (CBD)</article-title><source>J Addiction Med</source><year>2021</year><volume>15</volume><fpage>355</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/adm.0000000000000771</pub-id><pub-id pub-id-type="pmcid">PMC8489583</pub-id><pub-id pub-id-type="pmid">33323690</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_016"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murthy</surname><given-names>P</given-names></name><name name-style="western"><surname>Narasimha</surname><given-names>VL</given-names></name></person-group><article-title>Effects of the COVID-19 pandemic and lockdown on alcohol use disorders and complications</article-title><source>Curr Opin Psychiatr</source><year>2021</year><volume>34</volume><fpage>376</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1097/yco.0000000000000720</pub-id><pub-id pub-id-type="pmcid">PMC8183243</pub-id><pub-id pub-id-type="pmid">34016817</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_017"><label>17.</label><element-citation publication-type="book"><source>The drug overdose epidemic: behind the numbers [Internet]</source><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/opioids/data/index.html" ext-link-type="uri">https://www.cdc.gov/opioids/data/index.html</ext-link><comment>Accessed</comment><date-in-citation content-type="access">23 Nov 2022</date-in-citation></element-citation></ref><ref id="j_nipt-2023-0004_ref_018"><label>18.</label><element-citation publication-type="book"><source>Key substance use and mental health indicators in the United States: results from the 2019 national survey on drug use and health [Internet]</source><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.samhsa.gov/data/sites/default/files/reports/rpt29393/2019NSDUHFFRPDFWHTML/2019NSDUHFFR090120.htm" ext-link-type="uri">https://www.samhsa.gov/data/sites/default/files/reports/rpt29393/2019NSDUHFFRPDFWHTML/2019NSDUHFFR090120.htm</ext-link><comment>Accessed</comment><date-in-citation content-type="access">24 Nov 2022</date-in-citation></element-citation></ref><ref id="j_nipt-2023-0004_ref_019"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>S</given-names></name><name name-style="western"><surname>Paluszek</surname><given-names>MM</given-names></name><name name-style="western"><surname>Rachor</surname><given-names>GS</given-names></name><name name-style="western"><surname>McKay</surname><given-names>D</given-names></name><name name-style="western"><surname>Asmundson</surname><given-names>GJG</given-names></name></person-group><article-title>Substance use and abuse, COVID-19-related distress, and disregard for social distancing: a network analysis</article-title><source>Addict Behav</source><year>2021</year><volume>114</volume><fpage>106754</fpage><pub-id pub-id-type="doi">10.1016/j.addbeh.2020.106754</pub-id><pub-id pub-id-type="pmid">33310690</pub-id><pub-id pub-id-type="pmcid">PMC8164919</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_020"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahorik</surname><given-names>AL</given-names></name><name name-style="western"><surname>Satre</surname><given-names>DD</given-names></name><name name-style="western"><surname>Kline-Simon</surname><given-names>AH</given-names></name><name name-style="western"><surname>Weisner</surname><given-names>CM</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>CI</given-names></name></person-group><article-title>Alcohol, cannabis, and opioid use disorders, and disease burden in an integrated health care system</article-title><source>J Addiction Med</source><year>2017</year><volume>11</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/adm.0000000000000260</pub-id><pub-id pub-id-type="pmcid">PMC5291754</pub-id><pub-id pub-id-type="pmid">27610582</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_021"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>H</given-names></name><name name-style="western"><surname>Newton</surname><given-names>C</given-names></name><name name-style="western"><surname>Klein</surname><given-names>TW</given-names></name></person-group><article-title>Microbial infections, immunomodulation, and drugs of abuse</article-title><source>Clin Microbiol Rev</source><year>2003</year><volume>16</volume><fpage>209</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1128/cmr.16.2.209-219.2003</pub-id><pub-id pub-id-type="pmid">12692094</pub-id><pub-id pub-id-type="pmcid">PMC153143</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_022"><label>22.</label><element-citation publication-type="book"><source>Drugs, brains, and behavior: the science of addiction [Internet]</source><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/addiction-health" ext-link-type="uri">https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/addiction-health</ext-link><comment>Accessed</comment><date-in-citation content-type="access">24 Nov 2022</date-in-citation></element-citation></ref><ref id="j_nipt-2023-0004_ref_023"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T</given-names></name><name name-style="western"><surname>Du</surname><given-names>R</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1054</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id><pub-id pub-id-type="pmcid">PMC7270627</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_024"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>S</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>JS</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>M</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>JM</given-names></name><name name-style="western"><surname>McGinn</surname><given-names>T</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>2052</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.6775</pub-id><pub-id pub-id-type="pmid">32320003</pub-id><pub-id pub-id-type="pmcid">PMC7177629</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_025"><label>25.</label><element-citation publication-type="book"><source>Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals [Internet]</source><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html" ext-link-type="uri">https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html</ext-link><comment>Accessed</comment><date-in-citation content-type="access">25 Nov 2022</date-in-citation></element-citation></ref><ref id="j_nipt-2023-0004_ref_026"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calvey</surname><given-names>T</given-names></name><name name-style="western"><surname>Scheibein</surname><given-names>F</given-names></name><name name-style="western"><surname>Saad</surname><given-names>NA</given-names></name><name name-style="western"><surname>Shirasaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Dannatt</surname><given-names>L</given-names></name><name name-style="western"><surname>Stowe</surname><given-names>M</given-names></name><etal/></person-group><article-title>The changing landscape of alcohol use and alcohol use disorder during the COVID-19 pandemic &#8211; perspectives of early career professionals in 16 countries</article-title><source>J Addiction Med</source><year>2020</year><volume>14</volume><fpage>e284</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/adm.0000000000000735</pub-id><pub-id pub-id-type="pmid">32909983</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_027"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melamed</surname><given-names>O</given-names></name><name name-style="western"><surname>Hauck</surname><given-names>T</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>L</given-names></name><name name-style="western"><surname>Selby</surname><given-names>P</given-names></name><name name-style="western"><surname>Mulsant</surname><given-names>B</given-names></name></person-group><article-title>COVID-19 and persons with substance use disorders: inequities and mitigation strategies</article-title><source>Subst Abuse</source><year>2020</year><volume>41</volume><fpage>286</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1080/08897077.2020.1784363</pub-id><pub-id pub-id-type="pmid">32697172</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_028"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bailey</surname><given-names>KL</given-names></name><name name-style="western"><surname>Samuelson</surname><given-names>DR</given-names></name><name name-style="western"><surname>Wyatt</surname><given-names>TA</given-names></name></person-group><article-title>Alcohol use disorder: a pre-existing condition for COVID-19?</article-title><source>Alcohol</source><year>2021</year><volume>90</volume><fpage>11</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.alcohol.2020.10.003</pub-id><pub-id pub-id-type="pmid">33080339</pub-id><pub-id pub-id-type="pmcid">PMC7568767</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_029"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seitz</surname><given-names>HK</given-names></name><name name-style="western"><surname>Bataller</surname><given-names>R</given-names></name><name name-style="western"><surname>Cortez-Pinto</surname><given-names>H</given-names></name><name name-style="western"><surname>Gao</surname><given-names>B</given-names></name><name name-style="western"><surname>Gual</surname><given-names>A</given-names></name><name name-style="western"><surname>Lackner</surname><given-names>C</given-names></name><etal/></person-group><article-title>Alcoholic liver disease</article-title><source>Nat Rev Dis Prim</source><year>2018</year><volume>4</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1038/s41572-018-0014-7</pub-id><pub-id pub-id-type="pmid">30115921</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_030"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simet</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sisson</surname><given-names>JH</given-names></name></person-group><article-title>Alcohol&#8217;s effects on lung health and immunity</article-title><source>Alcohol Res</source><year>2015</year><volume>37</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">26695745</pub-id><pub-id pub-id-type="pmcid">PMC4590617</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_031"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubey</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>R</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>P</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Dubey</surname><given-names>S</given-names></name></person-group><article-title>COVID-19 and addiction</article-title><source>Diabetes Metabol Syndr</source><year>2020</year><volume>14</volume><fpage>817</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.dsx.2020.06.008</pub-id><pub-id pub-id-type="pmcid">PMC7282772</pub-id><pub-id pub-id-type="pmid">32540735</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_032"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhammad</surname><given-names>JS</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>R</given-names></name><name name-style="western"><surname>Khan</surname><given-names>NA</given-names></name></person-group><article-title>COVID-19: is there a link between alcohol abuse and SARS-CoV-2-induced severe neurological manifestations?</article-title><source>ACS Pharmacol Transl Sci</source><year>2021</year><volume>4</volume><fpage>1024</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1021/acsptsci.1c00073</pub-id><pub-id pub-id-type="pmid">33860221</pub-id><pub-id pub-id-type="pmcid">PMC8033744</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_033"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>CV</given-names></name><name name-style="western"><surname>Horcajadas</surname><given-names>FA</given-names></name><name name-style="western"><surname>Arroba</surname><given-names>CMA</given-names></name><name name-style="western"><surname>Ripoll</surname><given-names>CC</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Pajares</surname><given-names>ME</given-names></name><etal/></person-group><article-title>COVID-19-Related neuropsychiatric symptoms in patients with alcohol abuse conditions during the SARS-CoV-2 pandemic: a retrospective cohort study using real world data from electronic health records of a tertiary hospital</article-title><source>Front Neurol</source><year>2021</year><volume>12</volume><fpage>630566</fpage><pub-id pub-id-type="doi">10.3389/fneur.2021.630566</pub-id><pub-id pub-id-type="pmid">33746884</pub-id><pub-id pub-id-type="pmcid">PMC7966461</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_034"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friske</surname><given-names>MM</given-names></name><name name-style="western"><surname>Giannone</surname><given-names>F</given-names></name><name name-style="western"><surname>Senger</surname><given-names>M</given-names></name><name name-style="western"><surname>Seitz</surname><given-names>R</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>AC</given-names></name><name name-style="western"><surname>Spanagel</surname><given-names>R</given-names></name></person-group><article-title>Chronic alcohol intake regulates expression of SARS-CoV2 infection-relevant genes in an organ-specific manner</article-title><source>Alcohol Clin Exp Res</source><year>2023</year><volume>47</volume><fpage>76</fpage><lpage>86</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acer.14981</pub-id><pub-id pub-id-type="pmid">36774629</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_035"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chick</surname><given-names>J</given-names></name></person-group><article-title>Alcohol and COVID-19</article-title><source>Alcohol Alcohol</source><year>2020</year><volume>55</volume><fpage>341</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1093/alcalc/agaa039</pub-id><pub-id pub-id-type="pmid">32400878</pub-id><pub-id pub-id-type="pmcid">PMC7239251</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_036"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szabo</surname><given-names>G</given-names></name><name name-style="western"><surname>Saha</surname><given-names>B</given-names></name></person-group><article-title>Alcohol&#8217;s effect on host defense</article-title><source>Alcohol Res</source><year>2015</year><volume>37</volume><fpage>159</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">26695755</pub-id><pub-id pub-id-type="pmcid">PMC4590613</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_037"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barr</surname><given-names>T</given-names></name><name name-style="western"><surname>Helms</surname><given-names>C</given-names></name><name name-style="western"><surname>Grant</surname><given-names>K</given-names></name><name name-style="western"><surname>Messaoudi</surname><given-names>I</given-names></name></person-group><article-title>Opposing effects of alcohol on the immune system</article-title><source>Prog Neuro Psychopharmacol Biol Psychiatry</source><year>2016</year><volume>65</volume><fpage>242</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2015.09.001</pub-id><pub-id pub-id-type="pmcid">PMC4911891</pub-id><pub-id pub-id-type="pmid">26375241</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_038"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Hodgkinson</surname><given-names>C</given-names></name><name name-style="western"><surname>Montero</surname><given-names>A</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>D</given-names></name><name name-style="western"><surname>Chang</surname><given-names>SL</given-names></name></person-group><article-title>Network meta-analysis on the mechanisms underlying alcohol augmentation of COVID-19 pathologies</article-title><source>Alcohol Clin Exp Res</source><year>2021</year><volume>45</volume><fpage>675</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1111/acer.14573</pub-id><pub-id pub-id-type="pmid">33583045</pub-id><pub-id pub-id-type="pmcid">PMC8014161</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_039"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simou</surname><given-names>E</given-names></name><name name-style="western"><surname>Britton</surname><given-names>J</given-names></name><name name-style="western"><surname>Leonardi-Bee</surname><given-names>J</given-names></name></person-group><article-title>Alcohol and the risk of pneumonia: a systematic review and meta-analysis</article-title><source>BMJ Open</source><year>2018</year><volume>8</volume><fpage>e022344</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2018-022344</pub-id><pub-id pub-id-type="pmcid">PMC6112384</pub-id><pub-id pub-id-type="pmid">30135186</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_040"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bilal</surname><given-names>B</given-names></name><name name-style="western"><surname>Saleem</surname><given-names>F</given-names></name><name name-style="western"><surname>Fatima</surname><given-names>SS</given-names></name></person-group><article-title>Alcohol consumption and obesity: the hidden scare with COVID-19 severity</article-title><source>Med Hypotheses</source><year>2020</year><volume>144</volume><fpage>110272</fpage><pub-id pub-id-type="doi">10.1016/j.mehy.2020.110272</pub-id><pub-id pub-id-type="pmid">33254576</pub-id><pub-id pub-id-type="pmcid">PMC7492811</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_041"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kianersi</surname><given-names>S</given-names></name><name name-style="western"><surname>Ludema</surname><given-names>C</given-names></name><name name-style="western"><surname>Macy</surname><given-names>JT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>M</given-names></name></person-group><article-title>Relationship between high-risk alcohol consumption and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion: a prospective sero-epidemiological cohort study among American college students</article-title><source>Addiction</source><year>2022</year><volume>117</volume><fpage>1908</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1111/add.15835</pub-id><pub-id pub-id-type="pmid">35129232</pub-id><pub-id pub-id-type="pmcid">PMC9111375</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_042"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Testino</surname><given-names>G</given-names></name></person-group><article-title>Are patients with alcohol use disorders at increased risk for covid-19 infection?</article-title><source>Alcohol Alcohol</source><year>2020</year><volume>55</volume><fpage>344</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/alcalc/agaa037</pub-id><pub-id pub-id-type="pmid">32400858</pub-id><pub-id pub-id-type="pmcid">PMC7239257</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_043"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>DP</given-names></name><name name-style="western"><surname>Lovegrove</surname><given-names>JA</given-names></name></person-group><article-title>Nutritional status of micronutrients as a possible and modifiable risk factor for COVID-19: a UK perspective</article-title><source>Br J Nutr</source><year>2021</year><volume>125</volume><fpage>678</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1017/s000711452000330x</pub-id><pub-id pub-id-type="pmid">32815493</pub-id><pub-id pub-id-type="pmcid">PMC7492581</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_044"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>BA</given-names></name><name name-style="western"><surname>Crill</surname><given-names>EM</given-names></name><name name-style="western"><surname>Franck</surname><given-names>CT</given-names></name><name name-style="western"><surname>Bickel</surname><given-names>WK</given-names></name><name name-style="western"><surname>Koffarnus</surname><given-names>MN</given-names></name></person-group><article-title>Blood nicotine predicts the behavioral economic abuse liability of reduced-nicotine cigarettes</article-title><source>Nicotine Tob Res</source><year>2022</year><volume>24</volume><fpage>728</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntab227</pub-id><pub-id pub-id-type="pmid">34865118</pub-id><pub-id pub-id-type="pmcid">PMC8962718</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_045"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samet</surname><given-names>JM</given-names></name></person-group><article-title>Tobacco products and the risks of SARS-CoV-2 infection and COVID-19</article-title><source>Nicotine Tob Res</source><year>2020</year><volume>22</volume><fpage>S93</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntaa187</pub-id><pub-id pub-id-type="pmid">33320258</pub-id><pub-id pub-id-type="pmcid">PMC7953960</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_046"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Zyl-Smit</surname><given-names>RN</given-names></name><name name-style="western"><surname>Richards</surname><given-names>G</given-names></name><name name-style="western"><surname>Leone</surname><given-names>FT</given-names></name></person-group><article-title>Tobacco smoking and COVID-19 infection</article-title><source>Lancet Respir Med</source><year>2020</year><volume>8</volume><fpage>664</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/s2213-2600(20)30239-3</pub-id><pub-id pub-id-type="pmid">32464099</pub-id><pub-id pub-id-type="pmcid">PMC7247798</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_047"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sifat</surname><given-names>AE</given-names></name><name name-style="western"><surname>Nozohouri</surname><given-names>S</given-names></name><name name-style="western"><surname>Villalba</surname><given-names>H</given-names></name><name name-style="western"><surname>Vaidya</surname><given-names>B</given-names></name><name name-style="western"><surname>Abbruscato</surname><given-names>TJ</given-names></name></person-group><article-title>The role of smoking and nicotine in the transmission and pathogenesis of COVID-19</article-title><source>J Pharmacol Exp Therapeut</source><year>2020</year><volume>375</volume><fpage>498</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1124/jpet.120.000170</pub-id><pub-id pub-id-type="pmcid">PMC7718727</pub-id><pub-id pub-id-type="pmid">33033170</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_048"><label>48.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Center for Chronic Disease P, Health Promotion Office on S, Health. Reports of the Surgeon General</collab></person-group><source>The health consequences of smoking&#8212;50 years of progress: a report of the surgeon general</source><publisher-loc>Atlanta (GA)</publisher-loc><publisher-name>Centers for Disease Control and Prevention (US)</publisher-name><year>2014</year></element-citation></ref><ref id="j_nipt-2023-0004_ref_049"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mrigpuri</surname><given-names>P</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Jha</surname><given-names>R</given-names></name><name name-style="western"><surname>Singla</surname><given-names>P</given-names></name><name name-style="western"><surname>Singla</surname><given-names>R</given-names></name></person-group><article-title>Tobacco use, tuberculosis and Covid-19: a lethal triad</article-title><source>Indian J Tubercul</source><year>2021</year><volume>68s</volume><fpage>S86</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.ijtb.2021.08.010</pub-id><pub-id pub-id-type="pmcid">PMC8359426</pub-id><pub-id pub-id-type="pmid">34538398</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_050"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>JM</given-names></name><name name-style="western"><surname>Sin</surname><given-names>DD</given-names></name></person-group><article-title>Smoking, ACE-2 and COVID-19: ongoing controversies</article-title><source>Eur Respir J</source><year>2020</year><volume>56</volume><fpage>2001759</fpage><pub-id pub-id-type="doi">10.1183/13993003.01759-2020</pub-id><pub-id pub-id-type="pmid">32430431</pub-id><pub-id pub-id-type="pmcid">PMC7363948</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_051"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XG</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>270</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_052"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashyap</surname><given-names>VK</given-names></name><name name-style="western"><surname>Dhasmana</surname><given-names>A</given-names></name><name name-style="western"><surname>Massey</surname><given-names>A</given-names></name><name name-style="western"><surname>Kotnala</surname><given-names>S</given-names></name><name name-style="western"><surname>Zafar</surname><given-names>N</given-names></name><name name-style="western"><surname>Jaggi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Smoking and COVID-19: adding fuel to the flame</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.3390/ijms21186581</pub-id><pub-id pub-id-type="pmcid">PMC7555793</pub-id><pub-id pub-id-type="pmid">32916821</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_053"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>JM</given-names></name><name name-style="western"><surname>Yang</surname><given-names>CX</given-names></name><name name-style="western"><surname>Sin</surname><given-names>DD</given-names></name></person-group><article-title>COVID-19 and nicotine as a mediator of ACE-2</article-title><source>Eur Respir J</source><year>2020</year><volume>55</volume><fpage>2001261</fpage><pub-id pub-id-type="doi">10.1183/13993003.01261-2020</pub-id><pub-id pub-id-type="pmid">32350104</pub-id><pub-id pub-id-type="pmcid">PMC7191112</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_054"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>JM</given-names></name><name name-style="western"><surname>Yang</surname><given-names>CX</given-names></name><name name-style="western"><surname>Tam</surname><given-names>A</given-names></name><name name-style="western"><surname>Shaipanich</surname><given-names>T</given-names></name><name name-style="western"><surname>Hackett</surname><given-names>TL</given-names></name><name name-style="western"><surname>Singhera</surname><given-names>GK</given-names></name><etal/></person-group><article-title>ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19</article-title><source>Eur Respir J</source><year>2020</year><volume>55</volume><fpage>2000688</fpage><pub-id pub-id-type="doi">10.1183/13993003.00688-2020</pub-id><pub-id pub-id-type="pmid">32269089</pub-id><pub-id pub-id-type="pmcid">PMC7144263</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_055"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallo</surname><given-names>O</given-names></name></person-group><article-title>Risk for COVID-19 infection in patients with tobacco smoke-associated cancers of the upper and lower airway</article-title><source>Eur Arch Oto-Rhino-Laryngol</source><year>2021</year><volume>278</volume><fpage>2695</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1007/s00405-020-06456-z</pub-id><pub-id pub-id-type="pmcid">PMC7677601</pub-id><pub-id pub-id-type="pmid">33216184</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_056"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maggi</surname><given-names>F</given-names></name><name name-style="western"><surname>Rosellini</surname><given-names>A</given-names></name><name name-style="western"><surname>Spezia</surname><given-names>PG</given-names></name><name name-style="western"><surname>Focosi</surname><given-names>D</given-names></name><name name-style="western"><surname>Macera</surname><given-names>L</given-names></name><name name-style="western"><surname>Lai</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nicotine upregulates ACE2 expression and increases competence for SARS-CoV-2 in human pneumocytes</article-title><source>ERJ Open Res</source><year>2021</year><volume>7</volume><fpage>00713</fpage><lpage>2020</lpage><pub-id pub-id-type="doi">10.1183/23120541.00713-2020</pub-id><pub-id pub-id-type="pmid">33850935</pub-id><pub-id pub-id-type="pmcid">PMC7942220</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_057"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>P</given-names></name><name name-style="western"><surname>Bonassi</surname><given-names>S</given-names></name><name name-style="western"><surname>Giacconi</surname><given-names>R</given-names></name><name name-style="western"><surname>Malavolta</surname><given-names>M</given-names></name><name name-style="western"><surname>Tomino</surname><given-names>C</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>F</given-names></name></person-group><article-title>COVID-19 and smoking: is nicotine the hidden link?</article-title><source>Eur Respir J</source><year>2020</year><volume>55</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1183/13993003.01116-2020</pub-id><pub-id pub-id-type="pmcid">PMC7236819</pub-id><pub-id pub-id-type="pmid">32341101</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_058"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lupacchini</surname><given-names>L</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>F</given-names></name><name name-style="western"><surname>Tomino</surname><given-names>C</given-names></name><name name-style="western"><surname>De Dominicis</surname><given-names>C</given-names></name><name name-style="western"><surname>Mollinari</surname><given-names>C</given-names></name><name name-style="western"><surname>Fini</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nicotine changes airway epithelial phenotype and may increase the SARS-COV-2 infection severity</article-title><source>Molecules</source><year>2021</year><volume>26</volume><fpage>101</fpage><pub-id pub-id-type="doi">10.3390/molecules26010101</pub-id><pub-id pub-id-type="pmcid">PMC7794754</pub-id><pub-id pub-id-type="pmid">33379366</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_059"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bojkova</surname><given-names>D</given-names></name><name name-style="western"><surname>Klann</surname><given-names>K</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B</given-names></name><name name-style="western"><surname>Widera</surname><given-names>M</given-names></name><name name-style="western"><surname>Krause</surname><given-names>D</given-names></name><name name-style="western"><surname>Ciesek</surname><given-names>S</given-names></name><etal/></person-group><article-title>Proteomics of SARS-CoV-2-infected host cells reveals therapy targets</article-title><source>Nature</source><year>2020</year><volume>583</volume><fpage>469</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2332-7</pub-id><pub-id pub-id-type="pmid">32408336</pub-id><pub-id pub-id-type="pmcid">PMC7616921</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_060"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patanavanich</surname><given-names>R</given-names></name><name name-style="western"><surname>Glantz</surname><given-names>SA</given-names></name></person-group><article-title>Smoking is associated with COVID-19 progression: a meta-analysis</article-title><source>Nicotine Tob Res</source><year>2020</year><volume>22</volume><fpage>1653</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntaa082</pub-id><pub-id pub-id-type="pmid">32399563</pub-id><pub-id pub-id-type="pmcid">PMC7239135</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_061"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mali&#324;ska</surname><given-names>D</given-names></name><name name-style="western"><surname>Wi&#281;ckowski</surname><given-names>MR</given-names></name><name name-style="western"><surname>Michalska</surname><given-names>B</given-names></name><name name-style="western"><surname>Drabik</surname><given-names>K</given-names></name><name name-style="western"><surname>Prill</surname><given-names>M</given-names></name><name name-style="western"><surname>Patalas-Krawczyk</surname><given-names>P</given-names></name><etal/></person-group><article-title>Mitochondria as a possible target for nicotine action</article-title><source>J Bioenerg Biomembr</source><year>2019</year><volume>51</volume><fpage>259</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1007/s10863-019-09800-z</pub-id><pub-id pub-id-type="pmid">31197632</pub-id><pub-id pub-id-type="pmcid">PMC6679833</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_062"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramaiah</surname><given-names>MJ</given-names></name></person-group><article-title>mTOR inhibition and p53 activation, microRNAs: the possible therapy against pandemic COVID-19</article-title><source>Gene Rep</source><year>2020</year><volume>20</volume><fpage>100765</fpage><pub-id pub-id-type="doi">10.1016/j.genrep.2020.100765</pub-id><pub-id pub-id-type="pmid">32835132</pub-id><pub-id pub-id-type="pmcid">PMC7324924</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_063"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jayaseelan</surname><given-names>VP</given-names></name><name name-style="western"><surname>Paramasivam</surname><given-names>A</given-names></name></person-group><article-title>Repurposing calcium channel blockers as antiviral drugs</article-title><source>J Cell Commun Signal</source><year>2020</year><volume>14</volume><fpage>467</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s12079-020-00579-y</pub-id><pub-id pub-id-type="pmid">32815099</pub-id><pub-id pub-id-type="pmcid">PMC7438026</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_064"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fillmore</surname><given-names>NR</given-names></name><name name-style="western"><surname>La</surname><given-names>J</given-names></name><name name-style="western"><surname>Szalat</surname><given-names>RE</given-names></name><name name-style="western"><surname>Tuck</surname><given-names>DP</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>V</given-names></name><name name-style="western"><surname>Yildirim</surname><given-names>C</given-names></name><etal/></person-group><article-title>Prevalence and outcome of COVID-19 infection in cancer patients: a national veterans affairs study</article-title><source>JNCI: J Natl Cancer Inst</source><year>2020</year><volume>113</volume><fpage>691</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/jnci/djaa159</pub-id><pub-id pub-id-type="pmcid">PMC7665587</pub-id><pub-id pub-id-type="pmid">33031532</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_065"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Changeux</surname><given-names>JP</given-names></name><name name-style="western"><surname>Amoura</surname><given-names>Z</given-names></name><name name-style="western"><surname>Rey</surname><given-names>FA</given-names></name><name name-style="western"><surname>Miyara</surname><given-names>M</given-names></name></person-group><article-title>A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications</article-title><source>C R Biol</source><year>2020</year><volume>343</volume><fpage>33</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.5802/crbiol.8</pub-id><pub-id pub-id-type="pmid">32720486</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_066"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farsalinos</surname><given-names>K</given-names></name><name name-style="western"><surname>Eliopoulos</surname><given-names>E</given-names></name><name name-style="western"><surname>Leonidas</surname><given-names>DD</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>GE</given-names></name><name name-style="western"><surname>Tzartos</surname><given-names>S</given-names></name><name name-style="western"><surname>Poulas</surname><given-names>K</given-names></name></person-group><article-title>Nicotinic cholinergic system and COVID-19: in silico identification of an interaction between SARS-CoV-2 and nicotinic receptors with potential therapeutic targeting implications</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>5807</fpage><pub-id pub-id-type="doi">10.3390/ijms21165807</pub-id><pub-id pub-id-type="pmid">32823591</pub-id><pub-id pub-id-type="pmcid">PMC7461543</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_067"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farsalinos</surname><given-names>K</given-names></name><name name-style="western"><surname>Niaura</surname><given-names>R</given-names></name><name name-style="western"><surname>Le Houezec</surname><given-names>J</given-names></name><name name-style="western"><surname>Barbouni</surname><given-names>A</given-names></name><name name-style="western"><surname>Tsatsakis</surname><given-names>A</given-names></name><name name-style="western"><surname>Kouretas</surname><given-names>D</given-names></name><etal/></person-group><article-title>Editorial: nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system</article-title><source>Toxicol Rep</source><year>2020</year><volume>7</volume><fpage>658</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.toxrep.2020.04.012</pub-id><pub-id pub-id-type="pmid">32355638</pub-id><pub-id pub-id-type="pmcid">PMC7192087</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_068"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagoumintzis</surname><given-names>G</given-names></name><name name-style="western"><surname>Chasapis</surname><given-names>CT</given-names></name><name name-style="western"><surname>Alexandris</surname><given-names>N</given-names></name><name name-style="western"><surname>Kouretas</surname><given-names>D</given-names></name><name name-style="western"><surname>Tzartos</surname><given-names>S</given-names></name><name name-style="western"><surname>Eliopoulos</surname><given-names>E</given-names></name><etal/></person-group><article-title>Nicotinic cholinergic system and COVID-19: in silico identification of interactions between &#945;7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins</article-title><source>Food Chem Toxicol</source><year>2021</year><volume>149</volume><fpage>112009</fpage><pub-id pub-id-type="doi">10.1016/j.fct.2021.112009</pub-id><pub-id pub-id-type="pmid">33503469</pub-id><pub-id pub-id-type="pmcid">PMC7830272</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_069"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alla</surname><given-names>F</given-names></name><name name-style="western"><surname>Berlin</surname><given-names>I</given-names></name><name name-style="western"><surname>Nguyen-Thanh</surname><given-names>V</given-names></name><name name-style="western"><surname>Guignard</surname><given-names>R</given-names></name><name name-style="western"><surname>Pasquereau</surname><given-names>A</given-names></name><name name-style="western"><surname>Quelet</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tobacco and COVID-19: a crisis within a crisis?</article-title><source>Can J Public Health</source><year>2020</year><volume>111</volume><fpage>995</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.17269/s41997-020-00427-x</pub-id><pub-id pub-id-type="pmid">33052586</pub-id><pub-id pub-id-type="pmcid">PMC7556572</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_070"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>AK</given-names></name><name name-style="western"><surname>Nethan</surname><given-names>ST</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>R</given-names></name></person-group><article-title>Tobacco use as a well-recognized cause of severe COVID-19 manifestations</article-title><source>Respir Med</source><year>2021</year><volume>176</volume><fpage>106233</fpage><pub-id pub-id-type="doi">10.1016/j.rmed.2020.106233</pub-id><pub-id pub-id-type="pmid">33253975</pub-id><pub-id pub-id-type="pmcid">PMC7674071</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_071"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oakes</surname><given-names>JM</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>RM</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>JD</given-names></name><name name-style="western"><surname>Lazartigues</surname><given-names>E</given-names></name><name name-style="western"><surname>Yue</surname><given-names>X</given-names></name></person-group><article-title>Nicotine and the renin-angiotensin system</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2018</year><volume>315</volume><fpage>R895</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.00099.2018</pub-id><pub-id pub-id-type="pmid">30088946</pub-id><pub-id pub-id-type="pmcid">PMC6295500</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_072"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koka</surname><given-names>V</given-names></name><name name-style="western"><surname>Huang</surname><given-names>XR</given-names></name><name name-style="western"><surname>Chung</surname><given-names>AC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Truong</surname><given-names>LD</given-names></name><name name-style="western"><surname>Lan</surname><given-names>HY</given-names></name></person-group><article-title>Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway</article-title><source>Am J Pathol</source><year>2008</year><volume>172</volume><fpage>1174</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2008.070762</pub-id><pub-id pub-id-type="pmid">18403595</pub-id><pub-id pub-id-type="pmcid">PMC2329828</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_073"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavezzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Troiani</surname><given-names>E</given-names></name><name name-style="western"><surname>Corrao</surname><given-names>S</given-names></name></person-group><article-title>COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review</article-title><source>Clin Pract</source><year>2020</year><volume>10</volume><fpage>1271</fpage><pub-id pub-id-type="doi">10.4081/cp.2020.1271</pub-id><pub-id pub-id-type="pmid">32509258</pub-id><pub-id pub-id-type="pmcid">PMC7267810</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_074"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H</given-names></name></person-group><article-title>Are healthy smokers really healthy?</article-title><source>Tob Induc Dis</source><year>2016</year><volume>14</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/s12971-016-0101-z</pub-id><pub-id pub-id-type="pmid">27891067</pub-id><pub-id pub-id-type="pmcid">PMC5111288</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_075"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bailey</surname><given-names>KL</given-names></name></person-group><article-title>The importance of the assessment of pulmonary function in COPD</article-title><source>Med Clin North Am</source><year>2012</year><volume>96</volume><fpage>745</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.mcna.2012.04.011</pub-id><pub-id pub-id-type="pmid">22793942</pub-id><pub-id pub-id-type="pmcid">PMC3998207</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_076"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R</given-names></name></person-group><article-title>Substance use disorder in the COVID-19 pandemic: a systematic review of vulnerabilities and complications</article-title><source>Pharmaceuticals</source><year>2020</year><volume>13</volume><fpage>155</fpage><pub-id pub-id-type="doi">10.3390/ph13070155</pub-id><pub-id pub-id-type="pmid">32708495</pub-id><pub-id pub-id-type="pmcid">PMC7407364</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_077"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Connor</surname><given-names>JP</given-names></name><name name-style="western"><surname>Stjepanovi&#263;</surname><given-names>D</given-names></name><name name-style="western"><surname>Le Foll</surname><given-names>B</given-names></name><name name-style="western"><surname>Hoch</surname><given-names>E</given-names></name><name name-style="western"><surname>Budney</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Hall</surname><given-names>WD</given-names></name></person-group><article-title>Cannabis use and cannabis use disorder</article-title><source>Nat Rev Dis Prim</source><year>2021</year><volume>7</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1038/s41572-021-00247-4</pub-id><pub-id pub-id-type="pmid">33627670</pub-id><pub-id pub-id-type="pmcid">PMC8655458</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_078"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>W</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></name></person-group><article-title>Adverse health effects of non-medical cannabis use</article-title><source>Lancet</source><year>2009</year><volume>374</volume><fpage>1383</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(09)61037-0</pub-id><pub-id pub-id-type="pmid">19837255</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_079"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cousijn</surname><given-names>J</given-names></name><name name-style="western"><surname>Kuhns</surname><given-names>L</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>H</given-names></name><name name-style="western"><surname>Kroon</surname><given-names>E</given-names></name></person-group><article-title>For better or for worse? A pre-post exploration of the impact of the COVID-19 lockdown on cannabis users</article-title><source>Addiction</source><year>2021</year><volume>116</volume><fpage>2104</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1111/add.15387</pub-id><pub-id pub-id-type="pmid">33394560</pub-id><pub-id pub-id-type="pmcid">PMC8254730</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_080"><label>80.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cabral</surname><given-names>GA</given-names></name><name name-style="western"><surname>Jamerson</surname><given-names>M</given-names></name></person-group><article-title>Chapter eight &#8211; marijuana use and brain immune mechanisms</article-title><person-group person-group-type="editor"><name name-style="western"><surname>Cui</surname><given-names>C</given-names></name><name name-style="western"><surname>Shurtleff</surname><given-names>D</given-names></name><name name-style="western"><surname>Harris</surname><given-names>RA</given-names></name></person-group><source>International review of neurobiology</source><publisher-loc>Cambridge, Massachusetts</publisher-loc><publisher-name>Academic Press</publisher-name><year>2014</year><volume>118</volume><fpage>199</fpage><lpage>230</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-801284-0.00008-7</pub-id><pub-id pub-id-type="pmid">25175866</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_081"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tashkin</surname><given-names>DP</given-names></name></person-group><article-title>Does smoking marijuana increase the risk of chronic obstructive pulmonary disease?</article-title><source>CMAJ</source><year>2009</year><volume>180</volume><fpage>797</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1503/cmaj.090142</pub-id><pub-id pub-id-type="pmid">19364782</pub-id><pub-id pub-id-type="pmcid">PMC2665954</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_082"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>WC</given-names></name><name name-style="western"><surname>Lo</surname><given-names>C</given-names></name><name name-style="western"><surname>Jong</surname><given-names>A</given-names></name><name name-style="western"><surname>Xing</surname><given-names>L</given-names></name><name name-style="western"><surname>FitzGerald</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Vollmer</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Marijuana and chronic obstructive lung disease: a population-based study</article-title><source>Canadian Medical Association Journal</source><year>2009</year><volume>180</volume><fpage>814</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1503/cmaj.081040</pub-id><pub-id pub-id-type="pmid">19364790</pub-id><pub-id pub-id-type="pmcid">PMC2665947</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_083"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suryavanshi</surname><given-names>SV</given-names></name><name name-style="western"><surname>Kovalchuk</surname><given-names>I</given-names></name><name name-style="western"><surname>Kovalchuk</surname><given-names>O</given-names></name></person-group><article-title>Cannabinoids as key regulators of inflammasome signaling: a current perspective</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>613613</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.613613</pub-id><pub-id pub-id-type="pmid">33584697</pub-id><pub-id pub-id-type="pmcid">PMC7876066</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_084"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>LC</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D</given-names></name><name name-style="western"><surname>Nicolaescu</surname><given-names>V</given-names></name><name name-style="western"><surname>Best</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Gula</surname><given-names>H</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses</article-title><source>Sci Adv</source><year>2022</year><volume>8</volume><fpage>eabi6110</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abi6110</pub-id><pub-id pub-id-type="pmid">35050692</pub-id><pub-id pub-id-type="pmcid">PMC11816653</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_085"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>LC</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D</given-names></name><name name-style="western"><surname>Nicolaescu</surname><given-names>V</given-names></name><name name-style="western"><surname>Best</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Ohtsuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>SN</given-names></name><etal/></person-group><article-title>Cannabidiol inhibits SARS-CoV-2 replication and promotes the host innate immune response</article-title><source>bioRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.03.10.432967</pub-id><pub-id pub-id-type="pmcid">PMC11816653</pub-id><pub-id pub-id-type="pmid">35050692</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_086"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>V</given-names></name><name name-style="western"><surname>Park</surname><given-names>JG</given-names></name><name name-style="western"><surname>Cho</surname><given-names>KH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>P</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T</given-names></name><name name-style="western"><surname>Ham</surname><given-names>J</given-names></name><etal/></person-group><article-title>Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches</article-title><source>Int J Biol Macromol</source><year>2021</year><volume>168</volume><fpage>474</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.12.020</pub-id><pub-id pub-id-type="pmid">33290767</pub-id><pub-id pub-id-type="pmcid">PMC7836687</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_087"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahmud</surname><given-names>MS</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>MS</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>ATMF</given-names></name><name name-style="western"><surname>Islam</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Sarker</surname><given-names>ME</given-names></name><name name-style="western"><surname>Islam</surname><given-names>MR</given-names></name></person-group><article-title>Antimicrobial and antiviral (SARS-CoV-2) potential of cannabinoids and cannabis sativa: a comprehensive review</article-title><source>Molecules</source><year>2021</year><volume>26</volume><fpage>7216</fpage><pub-id pub-id-type="doi">10.3390/molecules26237216</pub-id><pub-id pub-id-type="pmid">34885798</pub-id><pub-id pub-id-type="pmcid">PMC8658882</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_088"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tahamtan</surname><given-names>A</given-names></name><name name-style="western"><surname>Tavakoli-Yaraki</surname><given-names>M</given-names></name><name name-style="western"><surname>Salimi</surname><given-names>V</given-names></name></person-group><article-title>Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients</article-title><source>Expet Rev Respir Med</source><year>2020</year><volume>14</volume><fpage>965</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1080/17476348.2020.1787836</pub-id><pub-id pub-id-type="pmcid">PMC7441794</pub-id><pub-id pub-id-type="pmid">32576053</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_089"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirsch</surname><given-names>JS</given-names></name><name name-style="western"><surname>Ng</surname><given-names>JH</given-names></name><name name-style="western"><surname>Ross</surname><given-names>DW</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>Shah</surname><given-names>HH</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Acute kidney injury in patients hospitalized with COVID-19</article-title><source>Kidney Int</source><year>2020</year><volume>98</volume><fpage>209</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2020.05.006</pub-id><pub-id pub-id-type="pmid">32416116</pub-id><pub-id pub-id-type="pmcid">PMC7229463</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_090"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malinowska</surname><given-names>B</given-names></name><name name-style="western"><surname>Baranowska-Kuczko</surname><given-names>M</given-names></name><name name-style="western"><surname>Kicman</surname><given-names>A</given-names></name><name name-style="western"><surname>Schlicker</surname><given-names>E</given-names></name></person-group><article-title>Opportunities, challenges and pitfalls of using cannabidiol as an adjuvant drug in COVID-19</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>1</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.3390/ijms22041986</pub-id><pub-id pub-id-type="pmcid">PMC7922403</pub-id><pub-id pub-id-type="pmid">33671463</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_091"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costiniuk</surname><given-names>CT</given-names></name><name name-style="western"><surname>Jenabian</surname><given-names>MA</given-names></name></person-group><article-title>Acute inflammation and pathogenesis of SARS-CoV-2 infection: cannabidiol as a potential anti-inflammatory treatment?</article-title><source>Cytokine Growth Factor Rev</source><year>2020</year><volume>53</volume><fpage>63</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2020.05.008</pub-id><pub-id pub-id-type="pmid">32467020</pub-id><pub-id pub-id-type="pmcid">PMC7239000</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_092"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>F</given-names></name><name name-style="western"><surname>Tortora</surname><given-names>C</given-names></name><name name-style="western"><surname>Argenziano</surname><given-names>M</given-names></name><name name-style="western"><surname>Di Paola</surname><given-names>A</given-names></name><name name-style="western"><surname>Punzo</surname><given-names>F</given-names></name></person-group><article-title>Cannabinoid receptor type 2: a possible target in SARS-CoV-2 (CoV-19) infection?</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>3809</fpage><pub-id pub-id-type="doi">10.3390/ijms21113809</pub-id><pub-id pub-id-type="pmid">32471272</pub-id><pub-id pub-id-type="pmcid">PMC7312493</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_093"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Booz</surname><given-names>GW</given-names></name></person-group><article-title>Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress</article-title><source>Free Radic Biol Med</source><year>2011</year><volume>51</volume><fpage>1054</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2011.01.007</pub-id><pub-id pub-id-type="pmid">21238581</pub-id><pub-id pub-id-type="pmcid">PMC3085542</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_094"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Kovalchuk</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Rodriguez-Juarez</surname><given-names>R</given-names></name><name name-style="western"><surname>Ilnytskyy</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kovalchuk</surname><given-names>I</given-names></name><etal/></person-group><article-title>In search of preventive strategies: novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues</article-title><source>Aging</source><year>2020</year><volume>12</volume><fpage>22425</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.18632/aging.202225</pub-id><pub-id pub-id-type="pmid">33221759</pub-id><pub-id pub-id-type="pmcid">PMC7746344</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_095"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khodadadi</surname><given-names>H</given-names></name><name name-style="western"><surname>Salles</surname><given-names>&#201;L</given-names></name><name name-style="western"><surname>Jarrahi</surname><given-names>A</given-names></name><name name-style="western"><surname>Chibane</surname><given-names>F</given-names></name><name name-style="western"><surname>Costigliola</surname><given-names>V</given-names></name><name name-style="western"><surname>Yu</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Cannabidiol modulates cytokine storm in acute respiratory distress syndrome induced by simulated viral infection using synthetic RNA</article-title><source>Cannabis Cannabinoid Res</source><year>2020</year><volume>5</volume><fpage>197</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1089/can.2020.0043</pub-id><pub-id pub-id-type="pmid">32923657</pub-id><pub-id pub-id-type="pmcid">PMC7480719</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_096"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salles</surname><given-names>&#201;L</given-names></name><name name-style="western"><surname>Khodadadi</surname><given-names>H</given-names></name><name name-style="western"><surname>Jarrahi</surname><given-names>A</given-names></name><name name-style="western"><surname>Ahluwalia</surname><given-names>M</given-names></name><name name-style="western"><surname>Paffaro</surname><given-names>VA</given-names></name><name name-style="western"><surname>Costigliola</surname><given-names>V</given-names></name><etal/></person-group><article-title>Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome</article-title><source>J Cell Mol Med</source><year>2020</year><volume>24</volume><fpage>12869</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1111/jcmm.15883</pub-id><pub-id pub-id-type="pmid">33058425</pub-id><pub-id pub-id-type="pmcid">PMC7686987</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_097"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovalchuk</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Rodriguez-Juarez</surname><given-names>R</given-names></name><name name-style="western"><surname>Ilnytskyy</surname><given-names>S</given-names></name><name name-style="western"><surname>Kovalchuk</surname><given-names>I</given-names></name><etal/></person-group><article-title>Fighting the storm: could novel anti-TNF&#945; and anti-IL-6 C. Sativa cultivars tame cytokine storm in COVID-19?</article-title><source>Aging</source><year>2021</year><volume>13</volume><fpage>1571</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.18632/aging.202500</pub-id><pub-id pub-id-type="pmid">33465050</pub-id><pub-id pub-id-type="pmcid">PMC7880317</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_098"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anil</surname><given-names>SM</given-names></name><name name-style="western"><surname>Shalev</surname><given-names>N</given-names></name><name name-style="western"><surname>Vinayaka</surname><given-names>AC</given-names></name><name name-style="western"><surname>Nadarajan</surname><given-names>S</given-names></name><name name-style="western"><surname>Namdar</surname><given-names>D</given-names></name><name name-style="western"><surname>Belausov</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>1462</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-81049-2</pub-id><pub-id pub-id-type="pmid">33446817</pub-id><pub-id pub-id-type="pmcid">PMC7809280</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_099"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallily</surname><given-names>R</given-names></name><name name-style="western"><surname>Yekhtin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hanu</surname><given-names>LO</given-names></name></person-group><article-title>Overcoming the bell-shaped dose-response of cannabidiol by using <italic toggle="yes">cannabis</italic> extract enriched in cannabidiol</article-title><source>Pharmacol Pharm</source><year>2015</year><volume>06</volume><fpage>11</fpage></element-citation></ref><ref id="j_nipt-2023-0004_ref_100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mamber</surname><given-names>SW</given-names></name><name name-style="western"><surname>Krakowka</surname><given-names>S</given-names></name><name name-style="western"><surname>Osborn</surname><given-names>J</given-names></name><name name-style="western"><surname>Saberski</surname><given-names>L</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>RG</given-names></name><name name-style="western"><surname>Dahlberg</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Can unconventional immunomodulatory agents help alleviate COVID-19 symptoms and severity?</article-title><source>mSphere</source><year>2020</year><volume>5</volume><fpage>e00288</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1128/msphere.00288-20</pub-id><pub-id pub-id-type="pmid">32404512</pub-id><pub-id pub-id-type="pmcid">PMC7227768</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucaciu</surname><given-names>O</given-names></name><name name-style="western"><surname>Aghiorghiesei</surname><given-names>O</given-names></name><name name-style="western"><surname>Petrescu</surname><given-names>NB</given-names></name><name name-style="western"><surname>Mirica</surname><given-names>IC</given-names></name><name name-style="western"><surname>Benea</surname><given-names>HRC</given-names></name><name name-style="western"><surname>Apostu</surname><given-names>D</given-names></name></person-group><article-title>In quest of a new therapeutic approach in COVID-19: the endocannabinoid system</article-title><source>Drug Metabol Rev</source><year>2021</year><volume>53</volume><fpage>478</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1080/03602532.2021.1895204</pub-id><pub-id pub-id-type="pmcid">PMC7989954</pub-id><pub-id pub-id-type="pmid">33683968</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merad</surname><given-names>M</given-names></name><name name-style="western"><surname>Martin</surname><given-names>JC</given-names></name></person-group><article-title>Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><fpage>355</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0331-4</pub-id><pub-id pub-id-type="pmid">32376901</pub-id><pub-id pub-id-type="pmcid">PMC7201395</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>SC</given-names></name></person-group><article-title>Structure of SARS coronavirus spike receptor-binding domain complexed with receptor</article-title><source>Science</source><year>2005</year><volume>309</volume><fpage>1864</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1126/science.1116480</pub-id><pub-id pub-id-type="pmid">16166518</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Grinstein</surname><given-names>S</given-names></name></person-group><article-title>Phagocytosis and innate immunity</article-title><source>Curr Opin Immunol</source><year>2002</year><volume>14</volume><fpage>136</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/s0952-7915(01)00309-0</pub-id><pub-id pub-id-type="pmid">11790544</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lv</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>A CD36 synthetic peptide inhibits silica-induced lung fibrosis in the mice</article-title><source>Toxicol Ind Health</source><year>2010</year><volume>26</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1177/0748233709359274</pub-id><pub-id pub-id-type="pmid">20056742</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatoum</surname><given-names>AS</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>CL</given-names></name><name name-style="western"><surname>Colbert</surname><given-names>SMC</given-names></name><name name-style="western"><surname>Winiger</surname><given-names>EA</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>EC</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Genetic liability to cannabis use disorder and COVID-19 hospitalization</article-title><source>Biol. Psychiatr. Global Open Sci.</source><year>2021</year><volume>1</volume><fpage>317</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.bpsgos.2021.06.005</pub-id><pub-id pub-id-type="pmcid">PMC8214324</pub-id><pub-id pub-id-type="pmid">34235496</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borgonhi</surname><given-names>EM</given-names></name><name name-style="western"><surname>Volpatto</surname><given-names>VL</given-names></name><name name-style="western"><surname>Ornell</surname><given-names>F</given-names></name><name name-style="western"><surname>Rabelo-da-Ponte</surname><given-names>FD</given-names></name><name name-style="western"><surname>Kessler</surname><given-names>FHP</given-names></name></person-group><article-title>Multiple clinical risks for cannabis users during the COVID-19 pandemic</article-title><source>Addiction Sci Clin Pract</source><year>2021</year><volume>16</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1186/s13722-021-00214-0</pub-id><pub-id pub-id-type="pmcid">PMC7816063</pub-id><pub-id pub-id-type="pmid">33472704</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owen</surname><given-names>KP</given-names></name><name name-style="western"><surname>Sutter</surname><given-names>ME</given-names></name><name name-style="western"><surname>Albertson</surname><given-names>TE</given-names></name></person-group><article-title>Marijuana: respiratory tract effects</article-title><source>Clin Rev Allergy Immunol</source><year>2014</year><volume>46</volume><fpage>65</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1007/s12016-013-8374-y</pub-id><pub-id pub-id-type="pmid">23715638</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasmin</surname><given-names>F</given-names></name><name name-style="western"><surname>Najeeb</surname><given-names>H</given-names></name><name name-style="western"><surname>Asghar</surname><given-names>MS</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>I</given-names></name><name name-style="western"><surname>Islam</surname><given-names>SMS</given-names></name></person-group><article-title>Increased COVID-19 infection risk, COVID-19 vaccine inaccessibility, and unacceptability: worrisome trio for patients with substance abuse disorders</article-title><source>J Glob Health</source><year>2021</year><volume>11</volume><fpage>03106</fpage><pub-id pub-id-type="doi">10.7189/jogh.11.03106</pub-id><pub-id pub-id-type="pmid">34671459</pub-id><pub-id pub-id-type="pmcid">PMC8501395</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maggirwar</surname><given-names>SB</given-names></name><name name-style="western"><surname>Khalsa</surname><given-names>JH</given-names></name></person-group><article-title>The link between cannabis use, immune system, and viral infections</article-title><source>Viruses</source><year>2021</year><volume>13</volume><fpage>1</fpage><volume>13</volume><pub-id pub-id-type="doi">10.3390/v13061099</pub-id><pub-id pub-id-type="pmcid">PMC8229290</pub-id><pub-id pub-id-type="pmid">34207524</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silverman</surname><given-names>MN</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>BD</given-names></name><name name-style="western"><surname>Biron</surname><given-names>CA</given-names></name><name name-style="western"><surname>Miller</surname><given-names>AH</given-names></name></person-group><article-title>Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection</article-title><source>Viral Immunol</source><year>2005</year><volume>18</volume><fpage>41</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1089/vim.2005.18.41</pub-id><pub-id pub-id-type="pmid">15802953</pub-id><pub-id pub-id-type="pmcid">PMC1224723</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>K</given-names></name><name name-style="western"><surname>Sinclair</surname><given-names>JE</given-names></name><name name-style="western"><surname>Sadeghirad</surname><given-names>H</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>JF</given-names></name><name name-style="western"><surname>Short</surname><given-names>KR</given-names></name><name name-style="western"><surname>Kulasinghe</surname><given-names>A</given-names></name></person-group><article-title>Cardiovascular disease in SARS-CoV-2 infection</article-title><source>Clin Transl Immunol</source><year>2021</year><volume>10</volume><fpage>e1343</fpage><pub-id pub-id-type="doi">10.1002/cti2.1343</pub-id><pub-id pub-id-type="pmcid">PMC8423130</pub-id><pub-id pub-id-type="pmid">34512975</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goyal</surname><given-names>H</given-names></name><name name-style="western"><surname>Awad</surname><given-names>HH</given-names></name><name name-style="western"><surname>Ghali</surname><given-names>JK</given-names></name></person-group><article-title>Role of cannabis in cardiovascular disorders</article-title><source>J Thorac Dis</source><year>2017</year><volume>9</volume><fpage>2079</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.21037/jtd.2017.06.104</pub-id><pub-id pub-id-type="pmid">28840009</pub-id><pub-id pub-id-type="pmcid">PMC5542986</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zakeri</surname><given-names>A</given-names></name><name name-style="western"><surname>Jadhav</surname><given-names>AP</given-names></name><name name-style="western"><surname>Sullenger</surname><given-names>BA</given-names></name><name name-style="western"><surname>Nimjee</surname><given-names>SM</given-names></name></person-group><article-title>Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist</article-title><source>J Neurointerventional Surg</source><year>2021</year><volume>13</volume><fpage>202</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/neurintsurg-2020-016794</pub-id><pub-id pub-id-type="pmid">33298508</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>BA</given-names></name><name name-style="western"><surname>Augustson</surname><given-names>EM</given-names></name><name name-style="western"><surname>Moser</surname><given-names>RP</given-names></name><name name-style="western"><surname>Budney</surname><given-names>AJ</given-names></name></person-group><article-title>Respiratory effects of marijuana and tobacco use in a U.S. sample</article-title><source>J Gen Intern Med</source><year>2005</year><volume>20</volume><fpage>33</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1525-1497.2004.40081.x</pub-id><pub-id pub-id-type="pmid">15693925</pub-id><pub-id pub-id-type="pmcid">PMC1490047</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strang</surname><given-names>J</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>M</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K</given-names></name><name name-style="western"><surname>Koob</surname><given-names>GF</given-names></name><etal/></person-group><article-title>Opioid use disorder</article-title><source>Nat Rev Dis Prim</source><year>2020</year><volume>6</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1038/s41572-019-0137-5</pub-id><pub-id pub-id-type="pmid">31919349</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shanthanna</surname><given-names>H</given-names></name><name name-style="western"><surname>Strand</surname><given-names>NH</given-names></name><name name-style="western"><surname>Provenzano</surname><given-names>DA</given-names></name><name name-style="western"><surname>Lobo</surname><given-names>CA</given-names></name><name name-style="western"><surname>Eldabe</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>A</given-names></name><etal/></person-group><article-title>Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel</article-title><source>Anaesthesia</source><year>2020</year><volume>75</volume><fpage>935</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1111/anae.15076</pub-id><pub-id pub-id-type="pmid">32259288</pub-id><pub-id pub-id-type="pmcid">PMC7262200</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>DG</given-names></name></person-group><article-title>Opioids and the COVID-19 pandemic: does chronic opioid use or misuse increase clinical vulnerability?</article-title><source>Br J Anaesth</source><year>2020</year><volume>125</volume><fpage>e382</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.bja.2020.07.004</pub-id><pub-id pub-id-type="pmid">32768181</pub-id><pub-id pub-id-type="pmcid">PMC7368905</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schimmel</surname><given-names>J</given-names></name><name name-style="western"><surname>Manini</surname><given-names>AF</given-names></name></person-group><article-title>Opioid use disorder and COVID-19: biological plausibility for worsened outcomes</article-title><source>Subst Use Misuse</source><year>2020</year><volume>55</volume><fpage>1900</fpage><lpage>1</lpage><pub-id pub-id-type="doi">10.1080/10826084.2020.1791184</pub-id><pub-id pub-id-type="pmid">32657207</pub-id><pub-id pub-id-type="pmcid">PMC8687452</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kosten</surname><given-names>T</given-names></name><name name-style="western"><surname>Strang</surname><given-names>J</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name></person-group><article-title>Editorial: challenges to opioid use disorders during COVID-19</article-title><source>Am J Addict</source><year>2020</year><volume>29</volume><fpage>174</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1111/ajad.13031</pub-id><pub-id pub-id-type="pmid">32281130</pub-id><pub-id pub-id-type="pmcid">PMC7262307</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussey</surname><given-names>HH</given-names></name><name name-style="western"><surname>Katz</surname><given-names>S</given-names></name></person-group><article-title>Infections resulting from narcotic addiction; report of 102 cases</article-title><source>Am J Med</source><year>1950</year><volume>9</volume><fpage>186</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(50)90021-0</pub-id><pub-id pub-id-type="pmid">15432465</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ataei</surname><given-names>M</given-names></name><name name-style="western"><surname>Shirazi</surname><given-names>FM</given-names></name><name name-style="western"><surname>Lamarine</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Nakhaee</surname><given-names>S</given-names></name><name name-style="western"><surname>Mehrpour</surname><given-names>O</given-names></name></person-group><article-title>A double-edged sword of using opioids and COVID-19: a toxicological view</article-title><source>Subst Abuse Treat Prev Pol</source><year>2020</year><volume>15</volume><fpage>91</fpage><pub-id pub-id-type="doi">10.1186/s13011-020-00333-y</pub-id><pub-id pub-id-type="pmcid">PMC7711252</pub-id><pub-id pub-id-type="pmid">33272308</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willner</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><name name-style="western"><surname>Leong</surname><given-names>KW</given-names></name></person-group><article-title>Modeling SARS-CoV-2 infection in individuals with opioid use disorder with brain organoids</article-title><source>J Tissue Eng</source><year>2021</year><volume>12</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1177/2041731420985299</pub-id><pub-id pub-id-type="pmcid">PMC7934045</pub-id><pub-id pub-id-type="pmid">33738089</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>S</given-names></name><name name-style="western"><surname>Ninkovic</surname><given-names>J</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Charboneau</surname><given-names>RG</given-names></name><name name-style="western"><surname>Das</surname><given-names>S</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>R</given-names></name><etal/></person-group><article-title>Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections</article-title><source>J Neuroimmune Pharmacol</source><year>2011</year><volume>6</volume><fpage>442</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1007/s11481-011-9292-5</pub-id><pub-id pub-id-type="pmid">21789507</pub-id><pub-id pub-id-type="pmcid">PMC3601186</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hofford</surname><given-names>RS</given-names></name><name name-style="western"><surname>Russo</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kiraly</surname><given-names>DD</given-names></name></person-group><article-title>Neuroimmune mechanisms of psychostimulant and opioid use disorders</article-title><source>Eur J Neurosci</source><year>2019</year><volume>50</volume><fpage>2562</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/ejn.14143</pub-id><pub-id pub-id-type="pmid">30179286</pub-id><pub-id pub-id-type="pmcid">PMC6531363</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacagnina</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>PD</given-names></name><name name-style="western"><surname>Bilbo</surname><given-names>SD</given-names></name></person-group><article-title>Glial and neuroimmune mechanisms as critical modulators of drug use and abuse</article-title><source>Neuropsychopharmacology</source><year>2017</year><volume>42</volume><fpage>156</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1038/npp.2016.121</pub-id><pub-id pub-id-type="pmid">27402494</pub-id><pub-id pub-id-type="pmcid">PMC5143481</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troyer</surname><given-names>EA</given-names></name><name name-style="western"><surname>Kohn</surname><given-names>JN</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S</given-names></name></person-group><article-title>Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms</article-title><source>Brain Behav Immun</source><year>2020</year><volume>87</volume><fpage>34</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2020.04.027</pub-id><pub-id pub-id-type="pmid">32298803</pub-id><pub-id pub-id-type="pmcid">PMC7152874</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice</article-title><source>J Virol</source><year>2010</year><volume>84</volume><fpage>9318</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1128/jvi.01049-10</pub-id><pub-id pub-id-type="pmid">20610717</pub-id><pub-id pub-id-type="pmcid">PMC2937604</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Althobaiti</surname><given-names>YS</given-names></name><name name-style="western"><surname>Alzahrani</surname><given-names>MA</given-names></name><name name-style="western"><surname>Alsharif</surname><given-names>NA</given-names></name><name name-style="western"><surname>Alrobaie</surname><given-names>NS</given-names></name><name name-style="western"><surname>Alsaab</surname><given-names>HO</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>MN</given-names></name></person-group><article-title>The possible relationship between the abuse of tobacco, opioid, or alcohol with COVID-19</article-title><source>Healthcare</source><year>2021</year><volume>9</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.3390/healthcare9010002</pub-id><pub-id pub-id-type="pmcid">PMC7822153</pub-id><pub-id pub-id-type="pmid">33375144</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dong</surname><given-names>L</given-names></name><etal/></person-group><article-title>Kidney disease is associated with in-hospital death of patients with COVID-19</article-title><source>Kidney Int</source><year>2020</year><volume>97</volume><fpage>829</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2020.03.005</pub-id><pub-id pub-id-type="pmid">32247631</pub-id><pub-id pub-id-type="pmcid">PMC7110296</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babu</surname><given-names>KM</given-names></name><name name-style="western"><surname>Brent</surname><given-names>J</given-names></name><name name-style="western"><surname>Juurlink</surname><given-names>DN</given-names></name></person-group><article-title>Prevention of opioid overdose</article-title><source>N Engl J Med</source><year>2019</year><volume>380</volume><fpage>2246</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1056/nejmra1807054</pub-id><pub-id pub-id-type="pmid">31167053</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bundy</surname><given-names>JD</given-names></name><name name-style="western"><surname>Bazzano</surname><given-names>LA</given-names></name><name name-style="western"><surname>Xie</surname><given-names>D</given-names></name><name name-style="western"><surname>Cohan</surname><given-names>J</given-names></name><name name-style="western"><surname>Dolata</surname><given-names>J</given-names></name><name name-style="western"><surname>Fink</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Self-reported tobacco, alcohol, and illicit drug use and progression of chronic kidney disease</article-title><source>Clin J Am Soc Nephrol</source><year>2018</year><volume>13</volume><fpage>993</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.2215/cjn.11121017</pub-id><pub-id pub-id-type="pmid">29880471</pub-id><pub-id pub-id-type="pmcid">PMC6032576</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dong</surname><given-names>L</given-names></name><etal/></person-group><article-title>Kidney impairment is associated with in-hospital death of COVID-19 patients</article-title><source>Kidney Int</source><year>2020</year><volume>97</volume><fpage>829</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">32247631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2020.03.005</pub-id><pub-id pub-id-type="pmcid">PMC7110296</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>G</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Q</given-names></name><name name-style="western"><surname>Guo</surname><given-names>E</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Multiple organ dysfunction syndrome, an unusual complication of heroin intoxication: a case report and review of literature</article-title><source>Int J Clin Exp Pathol</source><year>2015</year><volume>8</volume><fpage>11826</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">26617935</pub-id><pub-id pub-id-type="pmcid">PMC4637751</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porubsky</surname><given-names>S</given-names></name><name name-style="western"><surname>Kuppe</surname><given-names>C</given-names></name><name name-style="western"><surname>Maier</surname><given-names>T</given-names></name><name name-style="western"><surname>Birk</surname><given-names>HW</given-names></name><name name-style="western"><surname>W&#246;rnle</surname><given-names>M</given-names></name><name name-style="western"><surname>Moeller</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Renal lipidosis in patients enrolled in a methadone substitution program</article-title><source>Arch Pathol Lab Med</source><year>2014</year><volume>138</volume><fpage>689</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.5858/arpa.2013-0075-cr</pub-id><pub-id pub-id-type="pmid">24786128</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mellos</surname><given-names>E</given-names></name><name name-style="western"><surname>Paparrigopoulos</surname><given-names>T</given-names></name></person-group><article-title>Substance use during the COVID-19 pandemic: what is really happening?</article-title><source>Psychiatriki</source><year>2022</year><volume>33</volume><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.22365/jpsych.2022.072</pub-id><pub-id pub-id-type="pmid">35255473</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gu</surname><given-names>YH</given-names></name><name name-style="western"><surname>Liang</surname><given-names>LY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Concurrence of autophagy with apoptosis in alveolar epithelial cells contributes to chronic pulmonary toxicity induced by methamphetamine</article-title><source>Cell Prolif</source><year>2018</year><volume>51</volume><fpage>e12476</fpage><pub-id pub-id-type="doi">10.1111/cpr.12476</pub-id><pub-id pub-id-type="pmid">29956395</pub-id><pub-id pub-id-type="pmcid">PMC6528941</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LaVoie</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hastings</surname><given-names>TG</given-names></name></person-group><article-title>Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine</article-title><source>J Neurosci</source><year>1999</year><volume>19</volume><fpage>1484</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1523/jneurosci.19-04-01484.1999</pub-id><pub-id pub-id-type="pmid">9952424</pub-id><pub-id pub-id-type="pmcid">PMC6786023</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Courtney</surname><given-names>KE</given-names></name><name name-style="western"><surname>Ray</surname><given-names>LA</given-names></name></person-group><article-title>Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature</article-title><source>Drug Alcohol Depend</source><year>2014</year><volume>143</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2014.08.003</pub-id><pub-id pub-id-type="pmid">25176528</pub-id><pub-id pub-id-type="pmcid">PMC4164186</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hossain</surname><given-names>MK</given-names></name><name name-style="western"><surname>Hassanzadeganroudsari</surname><given-names>M</given-names></name><name name-style="western"><surname>Apostolopoulos</surname><given-names>V</given-names></name></person-group><article-title>Why METH users are at high risk of fatality due to COVID-19 infection?</article-title><source>Expert Rev Vaccines</source><year>2020</year><volume>19</volume><fpage>1101</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1080/14760584.2020.1858059</pub-id><pub-id pub-id-type="pmid">33249941</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chernyak</surname><given-names>BV</given-names></name><name name-style="western"><surname>Popova</surname><given-names>EN</given-names></name><name name-style="western"><surname>Prikhodko</surname><given-names>AS</given-names></name><name name-style="western"><surname>Grebenchikov</surname><given-names>OA</given-names></name><name name-style="western"><surname>Zinovkina</surname><given-names>LA</given-names></name><name name-style="western"><surname>Zinovkin</surname><given-names>RA</given-names></name></person-group><article-title>COVID-19 and oxidative stress</article-title><source>Biochemistry (Mosc)</source><year>2020</year><volume>85</volume><fpage>1543</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1134/s0006297920120068</pub-id><pub-id pub-id-type="pmid">33705292</pub-id><pub-id pub-id-type="pmcid">PMC7768996</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Agnillo</surname><given-names>F</given-names></name><name name-style="western"><surname>Walters</surname><given-names>KA</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>ZM</given-names></name><name name-style="western"><surname>Scherler</surname><given-names>K</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><etal/></person-group><article-title>Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19</article-title><source>Sci Transl Med</source><year>2021</year><volume>13</volume><fpage>eabj7790</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abj7790</pub-id><pub-id pub-id-type="pmid">34648357</pub-id><pub-id pub-id-type="pmcid">PMC11000440</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jayanthi</surname><given-names>S</given-names></name><name name-style="western"><surname>Daiwile</surname><given-names>AP</given-names></name><name name-style="western"><surname>Cadet</surname><given-names>JL</given-names></name></person-group><article-title>Neurotoxicity of methamphetamine: main effects and mechanisms</article-title><source>Exp Neurol</source><year>2021</year><volume>344</volume><fpage>113795</fpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2021.113795</pub-id><pub-id pub-id-type="pmid">34186102</pub-id><pub-id pub-id-type="pmcid">PMC8338805</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blaker</surname><given-names>AL</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>EA</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>BK</given-names></name></person-group><article-title>Neurotoxicity to dopamine neurons after the serial exposure to alcohol and methamphetamine: protection by COX-2 antagonism</article-title><source>Brain Behav Immun</source><year>2019</year><volume>81</volume><fpage>317</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2019.06.028</pub-id><pub-id pub-id-type="pmid">31228610</pub-id><pub-id pub-id-type="pmcid">PMC6754766</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baillargeon</surname><given-names>J</given-names></name><name name-style="western"><surname>Polychronopoulou</surname><given-names>E</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>YF</given-names></name><name name-style="western"><surname>Raji</surname><given-names>MA</given-names></name></person-group><article-title>The impact of substance use disorder on COVID-19 outcomes</article-title><source>Psychiatr Serv</source><year>2021</year><volume>72</volume><fpage>578</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1176/appi.ps.202000534</pub-id><pub-id pub-id-type="pmid">33138712</pub-id><pub-id pub-id-type="pmcid">PMC8089118</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhont</surname><given-names>S</given-names></name><name name-style="western"><surname>Derom</surname><given-names>E</given-names></name><name name-style="western"><surname>Van Braeckel</surname><given-names>E</given-names></name><name name-style="western"><surname>Depuydt</surname><given-names>P</given-names></name><name name-style="western"><surname>Lambrecht</surname><given-names>BN</given-names></name></person-group><article-title>The pathophysiology of &#8216;happy&#8217; hypoxemia in COVID-19</article-title><source>Respir Res</source><year>2020</year><volume>21</volume><fpage>198</fpage><pub-id pub-id-type="doi">10.1186/s12931-020-01462-5</pub-id><pub-id pub-id-type="pmid">32723327</pub-id><pub-id pub-id-type="pmcid">PMC7385717</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCarthy</surname><given-names>E</given-names></name><name name-style="western"><surname>McClain</surname><given-names>E</given-names></name></person-group><article-title>Methamphetamine-induced lung injury</article-title><source>Eur J Case Rep Intern Med</source><year>2019</year><volume>6</volume><fpage>001067</fpage><pub-id pub-id-type="doi">10.12890/2019_001067</pub-id><pub-id pub-id-type="pmid">31293988</pub-id><pub-id pub-id-type="pmcid">PMC6601696</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hingorani</surname><given-names>KS</given-names></name><name name-style="western"><surname>Bhadola</surname><given-names>S</given-names></name><name name-style="western"><surname>Cervantes-Arslanian</surname><given-names>AM</given-names></name></person-group><article-title>COVID-19 and the brain</article-title><source>Trends Cardiovasc Med</source><year>2022</year><volume>32</volume><fpage>323</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2022.04.004</pub-id><pub-id pub-id-type="pmid">35461991</pub-id><pub-id pub-id-type="pmcid">PMC9022395</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_149"><label>149.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>NIDA</collab></person-group><source>What is the scope of cocaine use in the United States?</source><year>2023</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://nida.nih.gov/publications/research-reports/cocaine/what-scope-cocaine-use-in-united-states" ext-link-type="uri">http://nida.nih.gov/publications/research-reports/cocaine/what-scope-cocaine-use-in-united-states</ext-link><comment>Accessed</comment><date-in-citation content-type="access">12 Apr 2023</date-in-citation></element-citation></ref><ref id="j_nipt-2023-0004_ref_150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreira</surname><given-names>FP</given-names></name><name name-style="western"><surname>Medeiros</surname><given-names>JR</given-names></name><name name-style="western"><surname>Lhullier</surname><given-names>AC</given-names></name><name name-style="western"><surname>Souza</surname><given-names>LD</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>K</given-names></name><name name-style="western"><surname>Portela</surname><given-names>LV</given-names></name><etal/></person-group><article-title>Cocaine abuse and effects in the serum levels of cytokines IL-6 and IL-10</article-title><source>Drug Alcohol Depend</source><year>2016</year><volume>158</volume><fpage>181</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.11.024</pub-id><pub-id pub-id-type="pmid">26679059</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darif</surname><given-names>D</given-names></name><name name-style="western"><surname>Hammi</surname><given-names>I</given-names></name><name name-style="western"><surname>Kihel</surname><given-names>A</given-names></name><name name-style="western"><surname>El Idrissi Saik</surname><given-names>I</given-names></name><name name-style="western"><surname>Guessous</surname><given-names>F</given-names></name><name name-style="western"><surname>Akarid</surname><given-names>K</given-names></name></person-group><article-title>The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong?</article-title><source>Microb Pathog</source><year>2021</year><volume>153</volume><fpage>104799</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2021.104799</pub-id><pub-id pub-id-type="pmid">33609650</pub-id><pub-id pub-id-type="pmcid">PMC7889464</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filho</surname><given-names>MT</given-names></name><name name-style="western"><surname>Yen</surname><given-names>CC</given-names></name><name name-style="western"><surname>Santos Ude</surname><given-names>P</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>DR</given-names></name></person-group><article-title>Pulmonary alterations in cocaine users</article-title><source>Sao Paulo Med J</source><year>2004</year><volume>122</volume><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1590/s1516-31802004000100007</pub-id><pub-id pub-id-type="pmid">15160524</pub-id><pub-id pub-id-type="pmcid">PMC11115353</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>QQ</given-names></name><name name-style="western"><surname>Kaelber</surname><given-names>DC</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></name></person-group><article-title>COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States</article-title><source>Mol Psychiatr</source><year>2021</year><volume>26</volume><fpage>30</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41380-020-00880-7</pub-id><pub-id pub-id-type="pmcid">PMC7488216</pub-id><pub-id pub-id-type="pmid">32929211</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>BG</given-names></name><name name-style="western"><surname>Rezkalla</surname><given-names>S</given-names></name><name name-style="western"><surname>Kloner</surname><given-names>RA</given-names></name></person-group><article-title>Cardiovascular effects of cocaine</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>2558</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1161/circulationaha.110.940569</pub-id><pub-id pub-id-type="pmid">21156654</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></name><name name-style="western"><surname>Berger</surname><given-names>NA</given-names></name><name name-style="western"><surname>Davis</surname><given-names>PB</given-names></name><name name-style="western"><surname>Kaelber</surname><given-names>DC</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name></person-group><article-title>Association of COVID-19 with endocarditis in patients with cocaine or opioid use disorders in the US</article-title><source>Mol Psychiatr</source><year>2023</year><volume>28</volume><fpage>543</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/s41380-022-01903-1</pub-id><pub-id pub-id-type="pmcid">PMC9918660</pub-id><pub-id pub-id-type="pmid">36510003</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Appenzeller</surname><given-names>F</given-names></name><name name-style="western"><surname>Gawaz</surname><given-names>M</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>I</given-names></name></person-group><article-title>Cocaine and COVID-19 in ST-elevation myocardial infarction</article-title><source>Case Rep Cardiol</source><year>2022</year><volume>2022</volume><fpage>5640965</fpage><pub-id pub-id-type="doi">10.1155/2022/5640965</pub-id><pub-id pub-id-type="pmid">35496656</pub-id><pub-id pub-id-type="pmcid">PMC9054480</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perper</surname><given-names>JA</given-names></name><name name-style="western"><surname>Van Thiel</surname><given-names>DH</given-names></name></person-group><article-title>Respiratory complications of cocaine abuse</article-title><source>Recent Dev Alcohol</source><year>1992</year><volume>10</volume><fpage>363</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1007/978-1-4899-1648-8_18</pub-id><pub-id pub-id-type="pmid">1589607</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Jahdhami</surname><given-names>I</given-names></name><name name-style="western"><surname>Al-Mawali</surname><given-names>A</given-names></name><name name-style="western"><surname>Bennji</surname><given-names>SM</given-names></name></person-group><article-title>Respiratory complications after COVID-19</article-title><source>Oman Med J</source><year>2022</year><volume>37</volume><fpage>e343</fpage><pub-id pub-id-type="doi">10.5001/omj.2022.52</pub-id><pub-id pub-id-type="pmid">35282425</pub-id><pub-id pub-id-type="pmcid">PMC8907756</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boldrini</surname><given-names>M</given-names></name><name name-style="western"><surname>Canoll</surname><given-names>PD</given-names></name><name name-style="western"><surname>Klein</surname><given-names>RS</given-names></name></person-group><article-title>How COVID-19 affects the brain</article-title><source>JAMA Psychiatr</source><year>2021</year><volume>78</volume><fpage>682</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2021.0500</pub-id><pub-id pub-id-type="pmcid">PMC9894299</pub-id><pub-id pub-id-type="pmid">33769431</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kandel</surname><given-names>DB</given-names></name></person-group><article-title>Does marijuana use cause the use of other drugs?</article-title><source>JAMA</source><year>2003</year><volume>289</volume><fpage>482</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1001/jama.289.4.482</pub-id><pub-id pub-id-type="pmid">12533129</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paland</surname><given-names>N</given-names></name><name name-style="western"><surname>Pechkovsky</surname><given-names>A</given-names></name><name name-style="western"><surname>Aswad</surname><given-names>M</given-names></name><name name-style="western"><surname>Hamza</surname><given-names>H</given-names></name><name name-style="western"><surname>Popov</surname><given-names>T</given-names></name><name name-style="western"><surname>Shahar</surname><given-names>E</given-names></name><etal/></person-group><article-title>The immunopathology of COVID-19 and the cannabis paradigm</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>631233</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.631233</pub-id><pub-id pub-id-type="pmid">33643316</pub-id><pub-id pub-id-type="pmcid">PMC7907157</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrareddy</surname><given-names>SN</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>M</given-names></name></person-group><article-title>SARS-CoV2 induced respiratory distress: can cannabinoids be added to anti-viral therapies to reduce lung inflammation?</article-title><source>Brain Behav Immun</source><year>2020</year><volume>87</volume><fpage>120</fpage><lpage>1</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2020.04.079</pub-id><pub-id pub-id-type="pmid">32360437</pub-id><pub-id pub-id-type="pmcid">PMC7187842</pub-id></element-citation></ref><ref id="j_nipt-2023-0004_ref_163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Breemen</surname><given-names>RB</given-names></name><name name-style="western"><surname>Muchiri</surname><given-names>RN</given-names></name><name name-style="western"><surname>Bates</surname><given-names>TA</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>JB</given-names></name><name name-style="western"><surname>Leier</surname><given-names>HC</given-names></name><name name-style="western"><surname>Farley</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cannabinoids block cellular entry of SARS-CoV-2 and the emerging variants</article-title><source>J Nat Prod</source><year>2022</year><volume>85</volume><fpage>176</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.1c00946</pub-id><pub-id pub-id-type="pmid">35007072</pub-id><pub-id pub-id-type="pmcid">PMC8768006</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>